



STS National Database™
Trusted. Transformed. Real-Time.

Intermacs

STS Intermacs

Quarterly Quality Assurance Report (2021 Q2) - Primary VAD Patients

HOSPX - DEMO SITE REPORT

Implant and event dates: January 1, 2020 to June 30, 2021

09/30/2021

Prepared by:

Intermacs Data Warehouse and Analytics Center
University of Alabama at Birmingham

James K. Kirklin, MD
Craig Collum, MPH
Ryan S. Cantor, PhD
Nick Timkovich, MSHI
Maceo Cleggett
Kathryn Hollifield, BSN RN

**CONFIDENTIAL: This information is only intended for:
HOSPX - DEMO SITE REPORT**

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

About This Report

The “Recent” version of the Quality Assurance report focuses on a contemporary cohort of patients. This report includes patients whose initial VAD was implanted within the previous 6 quarters.

The “Primary Patients” version of the report is limited to patients whose first device pre-implant form does not indicate prior VAD support.

Confidential

This report is intended only for STS Intermacs personnel at the hospital named on the cover of this report. Distribution of the report to other personnel within the hospital is left to the discretion of the STS Intermacs site administrator and physician representative. The STS Intermacs data in this report may not be distributed to anyone outside of your hospital. STS Intermacs has a separate mechanism for the creation and distribution of STS Intermacs aggregate data.

Disclaimer

STS Intermacs has attempted to create a high quality report that is a direct result of the data submitted by the STS Intermacs hospitals. However, STS Intermacs makes no warranties or representations, either expressed or implied, about the content of this report. STS Intermacs further disclaims any and all liability whatsoever in any information, material, or content of this report. Any reference in this report to any specific commercial product, service, manufacturer, or company does not constitute its endorsement or recommendation by STS Intermacs or its employees or agents. None of the material, information or content from this report shall serve as or create a contract between Intermacs and any person or entity accessing and using this report. The recipient of this report agrees to abide by the confidentiality laws of the United States, all other applicable federal and state laws, and applicable policies and guidelines of STS Intermacs. Comments involving information perceived as inaccurate, misleading, or inappropriate should be directed to: Maceo Cleggett with the Intermacs Data Warehouse and Analytics Center at INTERMACS-Reports@uabmc.edu.

This quarterly report includes clinical information from 75 patients receiving implants between January 1, 2020 and June 30, 2021 at HOSPX - DEMO SITE REPORT.

Table of Contents

- I. Introduction and Methods**
 - A. Purposes of this Report**
 - B. Source of Data and Limitations**
 - C. Statistical Summaries and Benchmarks for Quality Assurance**
 - D. Registry Compliance**
 - E. Future Reports**
 - F. Report Coverage - Patient Selection**
- II. Statistical Summaries and Benchmarks for Quality Assurance**
 - A. Pre-implant Summaries**
 - Demographics
 - Clinical Characteristics
 - Concerns and Contraindications
 - Hemodynamics
 - Functional Capacity and Quality of Life
 - Additional Interventions
 - B. Implant Summaries**
 - C. Post Implant Summary**
 - Adverse Event Rates
 - Adverse Event Timing
 - Time to First Device Malfunction and/or Thrombus
 - Time to First Infection
 - Time to First Neurological Dysfunction
 - Hospitals Days
 - 30 Day Readmission Rates
 - Functional Capacity
 - Quality of Life
 - D. Post Implant Risk Adjusted Outcomes**
 - E. Post Implant Outcomes**
 - Survival
 - Competing Outcomes
- III. Zone Conditions: Hemolysis, Hypertension, and Right Heart Failure**
 - Hemolysis
 - Hypertension
 - Right Heart Failure
- IV. Registry Compliance**
- V. Glossary**

Topics in **grey** are not part of this report, but will become part of future reports.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

I. Introduction and Methods

I.A. Purpose of this Report

As specified by the STS Intermacs Leadership, the primary goals of the registry are:

- Facilitate the refinement of patient selection to maximize outcomes with current and new device options.
- Identify predictors of good outcomes as well as risk factors for adverse events after device implantation.
- Develop consensus best practice guidelines to improve clinical management by reducing short and long term complications of MCSD therapy.
- Guide clinical application and evolution of next generation devices.
- Utilize Registry information to guide improvements in technology, particularly as next generation devices evolve.

Consistent with these goals, we have greatly expanded our site reports to move towards these goals at the hospital and patient level. Specifically, these reports will provide information in the following areas:

- Statistical Summaries and Benchmarks for Quality Assurance
- Patient Level Data
- Registry Compliance
- Data Quality Queries

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients***COVERAGE: January 1, 2020 - June 30, 2021******SITE: HOSPX - DEMO SITE REPORT*****I.B. Source of Data and Limitations**

The data in this report are based on all data entered into the STS Intermacs web-based data application through June 30, 2021. Patient enrollment in STS Intermacs began on June 23, 2006 and retrospective entry of patients with implants after March 1, 2006 was allowed. Your institution may have joined STS Intermacs at a later date and therefore your patient enrollment may have begun at a later date. This report is restricted to your patients who were implanted after your enrollment date and received a primary implant.

STS Intermacs is a registry that strives to meet the data quality standards of a prospective clinical trial. STS Intermacs is an on-going registry and therefore data quality efforts will always have an associated lag time.

As you review the data from your hospital that are contained in this report, you may find some information that appears incorrect or inconsistent. Please remember that this report is a direct function of the data that has been entered at your hospital. Therefore, please check any data issues with your online submitted data. The only caveat to this is that any corrections that you have made to your data since June 30, 2021 will not appear in this report. They will appear in the next quarterly report.

A registry that collects data on mechanical circulatory assist devices is necessarily complex. This complexity is the result of the support that the device provides (left ventricular support, right ventricular support, biventricular support, total heart support) and the potential for multiple exchanges within a patient. The major outcomes are just as complex because the standard outcome of death must be considered in the presence of transplantation and explant due to recovery of the heart. We have organized this report so that the pre-implant data represents all prospective device implants of LVAD, BiVAD or TAH. This is based on the organization of the STS Intermacs web-based data entry and will allow a complete picture of the patients and devices entered for your hospital.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

I.C. Statistical Summaries and Benchmarks for Quality Assurance

A primary purpose of this report is to provide statistical summaries of patients enrolled at the local hospital and to provide side-by-side comparisons of the hospital data with the data from the entire STS Intermacs Registry. Therefore these reports will provide the data information component of quality assurance where the hospital can compare both their patient mix with a national standard and will also be able to compare their outcomes after device implant with national results.

STS Intermacs is a valuable source of benchmarking according to what is occurring across the country in the MCSD community. This benchmark is not intended to imply good practice or bad practice but rather allows the hospital to compare the characteristics of their implanted patients with the patients from a national database.

I.D. Registry Compliance

Each hospital is evaluated for compliance and data entry.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

I.E. Future Reports

As previously stated, this report is a major step in greatly expanded quarterly reports from STS InterMACS. We will continue expansion of this report which will be the results of our pre-specified plans and feedback from the MCS D community.

Some of our specific plans include statistical summaries according to primary and secondary implants and also according to adult and pediatric patients. We also plan to add a section that summarizes the results of the initial screening log. This will include a frequency of the reasons for failing to obtain informed consent and a comparison to the national experience.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

I.F. Report Coverage - Inclusion / Exclusion Criteria

Starting 2020 Q4 the INTERMACS reports have been restructured to provide information from ALL patients enrolled in INTERMACS. To organize the information a series of reports is provided to compare patient characteristics and outcomes of different kinds of patients at your site with the aggregate INTERMACS cohort. The following report versions are created:

- Cumulative - All Patients
- Cumulative - Primary Patients
- Cumulative – Prior VAD Patients
- Recent - All Patients
- Recent - Primary Patients
- Recent – Prior VAD Patients

The CUMULATIVE report versions includes patients enrolled throughout the entire registry and is intended to provide a comprehensive set of long term outcomes. The RECENT report is limited to patients enrolled within the last rolling 6 quarters and provides information on contemporary patients.

The versions of the reports generated for ALL PATIENTS include all patients implanted within the report coverage dates. The PRIMARY PATIENTS versions are limited to patients that do not have a history of prior VAD reported on the pre-implant form of their first INTERMACS enrolled implant. The PRIOR VAD PATIENTS reports are limited to patients in which a prior VAD is indicated on their first enrolled pre-implant form.

There are a few administrative scenarios in which patients are excluded from the CUMULATIVE – ALL PATIENTS Report in order facilitate accurate comparisons to the aggregate INTERMACS data. The following patients are removed from all analyses:

- Retrospective Patients – the patient’s initial implant date is prior to your site’s activation in INTERMACS
- Implant, Pre-Implant, or Patient form not validated – patients missing a fully submitted implant, pre-implant, or patient form are not included because key data elements used in the reporting may be missing.
- Patient Implant Date Outside of Report Coverage – Patients implanted prior to the start of data collection June 23, 2006 or after the report coverage stop date December 31, 2020 are not include in the report.
- Pediatric Patients (Age <19 years at implant

Patients that meet these exclusion criteria are listed in “Exhibit 49: Patients Implanted at your Center but Excluded from the Cumulative - All Patient Report

The accompanying Data Quality Report lists all patients enrolled in STS Intermacs at your site.

Transfer patients and their subsequent experience are analyzed in the report for the site that implanted the patients first device enrolled in INTERMACS.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II. Statistical Summaries and Benchmarks for Quality Assurance

The first part of this section contains summary statistics of patients implanted (and enrolled in STS Intermacs) at your hospital. As a benchmark, the corresponding summary statistics for the entire Intermacs Registry are also provided. For explanations and/or definitions of the data elements go to the STS Intermacs User's Guide www.intermacs.org and select 'Intermacs Appendices', Appendix M/User's Guide'.

The summary statistics for continuous variables includes N (the number of patients with data), MEAN (the average value), STD (standard deviation), MIN (the smallest value), and MAX (the largest value).

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 1: Device Counts for Patients in this Report

The following tables list the number of implants received by patients meeting the inclusion criteria for this report. Subsequent exhibits are based on a patient level analysis. Characteristics are reported at the time of first implant. Unless noted otherwise, outcomes and follow-up include all information reported to INTERMACS for the patient.

NOTE: For most patients a second device indicates a device exchange. However, this count also includes the patients who receive a subsequent RVAD.

GROUP=HOSPX-9999

Device	IMPLANT DATE PERIOD						TOTAL
	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	
	n	n	n	n	n	n	
Primary Device	23	10	9	11	13	9	75
2nd Device	1	1	0	0	0	0	2
3rd Device	0	0	0	0	0	0	0
4th Device	0	0	0	0	0	0	0
5th Device	0	0	0	0	0	0	0

GROUP=STS Intermacs

Device	IMPLANT DATE PERIOD						TOTAL
	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	
	n	n	n	n	n	n	
Primary Device	768	550	681	536	560	526	3621
2nd Device	38	21	19	14	21	19	132
3rd Device	4	0	1	2	2	0	9
4th Device	0	0	0	0	0	0	0
5th Device	0	0	0	0	0	0	0

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Demographics****Exhibit 2: Age Group**

The following tables summarize age groups at your site and STS InterMACS over time.

AGE GROUP (yr)	HOSPX-9999													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
19-39	2	8.6 %	2	20.0 %	.	.	2	18.1 %	2	15.3 %	1	11.1 %	9	12.0 %
40-59	8	34.7 %	3	30.0 %	4	44.4 %	5	45.4 %	7	53.8 %	6	66.6 %	33	44.0 %
60-79	13	56.5 %	5	50.0 %	5	55.5 %	4	36.3 %	4	30.7 %	2	22.2 %	33	44.0 %
80+
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	11	100.0 %	13	100.0 %	9	100.0 %	75	100.0 %

AGE GROUP (yr)	STS InterMACS													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
19-39	81	10.5 %	62	11.2 %	93	13.6 %	64	11.9 %	73	13.0 %	71	13.4 %	444	12.2 %
40-59	307	39.9 %	230	41.8 %	267	39.2 %	201	37.5 %	218	38.9 %	203	38.5 %	1426	39.3 %
60-79	376	48.9 %	258	46.9 %	320	46.9 %	267	49.8 %	265	47.3 %	251	47.7 %	1737	47.9 %
80+	4	0.5 %	.	.	1	0.1 %	4	0.7 %	4	0.7 %	1	0.1 %	14	0.3 %
TOTAL	768	100.0 %	550	100.0 %	681	100.0 %	536	100.0 %	560	100.0 %	526	100.0 %	3621	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Demographics****Exhibit 3: Gender**

The following tables summarize gender at your site and STS Intermacs over time.

GENDER	HOSPX-9999													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Female	3	13.0 %	1	10.0 %	2	22.2 %	4	36.3 %	2	15.3 %	2	22.2 %	14	18.6 %
Male	20	86.9 %	9	90.0 %	7	77.7 %	7	63.6 %	11	84.6 %	7	77.7 %	61	81.3 %
Unspecified
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	11	100.0 %	13	100.0 %	9	100.0 %	75	100.0 %

GENDER	STS Intermacs													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Female	169	22.0 %	136	24.7 %	157	23.0 %	122	22.7 %	130	23.2 %	138	26.2 %	852	23.5 %
Male	599	77.9 %	414	75.2 %	523	76.7 %	414	77.2 %	429	76.6 %	388	73.7 %	2767	76.4 %
Unspecified	1	0.1 %	.	.	1	0.1 %	.	.	2	0.0 %
TOTAL	768	100.0 %	550	100.0 %	681	100.0 %	536	100.0 %	560	100.0 %	526	100.0 %	3621	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Demographics****Exhibit 4: Race**

The following tables summarize race at your site and STS InterMACS over time. The coordinator may check all that apply.

RACE	HOSPX-9999													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
African American	10	43.4 %	4	40.0 %	4	44.4 %	4	36.3 %	3	23.0 %	7	77.7 %	32	42.6 %
Other, Unknown, Undisclosed	5	21.7 %	1	10.0 %	3	33.3 %	4	36.3 %	6	46.1 %	.	.	19	25.3 %
White	8	34.7 %	5	50.0 %	2	22.2 %	3	27.2 %	4	30.7 %	2	22.2 %	24	32.0 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	11	100.0 %	13	100.0 %	9	100.0 %	75	100.0 %

RACE	STS InterMACS													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
African American	235	30.5 %	157	28.5 %	223	32.7 %	177	33.0 %	168	30.0 %	155	29.4 %	1115	30.7 %
Other, Unknown, Undisclosed	66	8.5 %	52	9.4 %	60	8.8 %	52	9.7 %	73	13.0 %	65	12.3 %	368	10.1 %
White	467	60.8 %	341	62.0 %	398	58.4 %	307	57.2 %	319	56.9 %	306	58.1 %	2138	59.0 %
TOTAL	768	100.0 %	550	100.0 %	681	100.0 %	536	100.0 %	560	100.0 %	526	100.0 %	3621	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Demographics****Exhibit 5: Hispanic Ethnicity**

The following tables summarize Hispanic ethnicity at your site and STS Intermacs over time.

HISPANIC ETHNICITY	HOSPX-9999													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Non-Hispanic	18	78.2 %	10	100.0 %	5	55.5 %	7	63.6 %	7	53.8 %	9	100.0 %	56	74.6 %
Unknown	4	17.3 %	.	.	2	22.2 %	3	27.2 %	2	15.3 %	.	.	11	14.6 %
Hispanic	1	4.3 %	.	.	2	22.2 %	1	9.0 %	4	30.7 %	.	.	8	10.6 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	11	100.0 %	13	100.0 %	9	100.0 %	75	100.0 %

HISPANIC ETHNICITY	STS Intermacs													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Non-Hispanic	694	90.3 %	498	90.5 %	618	90.7 %	475	88.6 %	497	88.7 %	468	88.9 %	3250	89.7 %
Unknown	30	3.9 %	19	3.4 %	22	3.2 %	24	4.4 %	14	2.5 %	21	3.9 %	130	3.5 %
Hispanic	44	5.7 %	33	6.0 %	41	6.0 %	37	6.9 %	49	8.7 %	37	7.0 %	241	6.6 %
TOTAL	768	100.0 %	550	100.0 %	681	100.0 %	536	100.0 %	560	100.0 %	526	100.0 %	3621	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 6. BSA**

The following tables summarize body surface area (BSA) at your site and STS Intermacs over time. BSA is a variable that is calculated based on the patient's height and weight. The Boyd calculation is used in this analysis.

GROUP=HOSPX-9999

PRE-IMPLANT BSA		2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	TOTAL
	N	23	10	9	11	13	9	75
	Mean	2.10	2.14	2.00	1.95	1.93	2.08	2.04
	Std	0.37	0.34	0.32	0.29	0.34	0.32	0.34
	Min	1.28	1.75	1.57	1.62	1.31	1.48	1.28
	Max	2.92	2.93	2.48	2.50	2.60	2.49	2.93

GROUP=STS Intermacs

PRE-IMPLANT BSA		2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	TOTAL
	N	767	548	680	536	560	526	3617
	Mean	2.10	2.07	2.11	2.09	2.07	2.12	2.09
	Std	0.32	0.32	0.33	0.32	0.32	0.33	0.32
	Min	0.96	1.05	0.50	0.77	1.15	1.16	0.50
	Max	3.33	3.31	3.23	3.39	2.95	3.38	3.39

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Clinical Characteristics****Exhibit 7. Device Strategy**

The following tables summarize pre-implant device strategy at your site and STS Intermacs over time.

PRE-IMPLANT DEVICE STRATEGY	HOSPX-9999													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
BTT - Listed	1	4.3 %	1	7.6 %	1	11.1 %	3	4.0 %
BTT - Likely	2	8.6 %	.	.	1	11.1 %	1	9.0 %	4	5.3 %
BTT - Moderate	1	4.3 %	3	30.0 %	.	.	2	18.1 %	6	8.0 %
BTT - Unlikely	.	.	1	10.0 %	1	1.3 %
Destination Therapy	19	82.6 %	6	60.0 %	8	88.8 %	8	72.7 %	11	84.6 %	8	88.8 %	60	80.0 %
Bridge to Recovery	1	7.6 %	.	.	1	1.3 %
Rescue Therapy
Other
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	11	100.0 %	13	100.0 %	9	100.0 %	75	100.0 %

PRE-IMPLANT DEVICE STRATEGY	STS Intermacs													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
BTT - Listed	41	5.3 %	43	7.8 %	47	6.9 %	32	5.9 %	33	5.8 %	25	4.7 %	221	6.1 %
BTT - Likely	46	5.9 %	34	6.1 %	39	5.7 %	24	4.4 %	26	4.6 %	17	3.2 %	186	5.1 %
BTT - Moderate	59	7.6 %	45	8.1 %	45	6.6 %	53	9.8 %	40	7.1 %	35	6.6 %	277	7.6 %
BTT - Unlikely	20	2.6 %	12	2.1 %	11	1.6 %	10	1.8 %	10	1.7 %	7	1.3 %	70	1.9 %
Destination Therapy	586	76.3 %	402	73.0 %	525	77.0 %	410	76.4 %	440	78.5 %	418	79.4 %	2781	76.8 %
Bridge to Recovery	6	0.7 %	1	0.1 %	2	0.2 %	.	.	3	0.5 %	1	0.1 %	13	0.3 %
Rescue Therapy	.	.	2	0.3 %	1	0.1 %	.	.	3	0.5 %	4	0.7 %	10	0.2 %
Other	10	1.3 %	11	2.0 %	11	1.6 %	7	1.3 %	5	0.8 %	19	3.6 %	63	1.7 %
TOTAL	768	100.0 %	550	100.0 %	681	100.0 %	536	100.0 %	560	100.0 %	526	100.0 %	3621	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 8. Patient Profile Levels

The following tables summarize pre-implant STS InterMACS patient profile levels at your site and STS InterMACS over time.

PRE-IMPLANT PATIENT PROFILE	HOSPX-9999													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
1 Critical Cardiogenic Shock	1	4.3 %	1	10.0 %	2	2.6 %
2 Progressive Decline	3	13.0 %	3	30.0 %	4	44.4 %	5	45.4 %	4	30.7 %	1	11.1 %	20	26.6 %
3 Stable but Inotrope Dependent	18	78.2 %	5	50.0 %	5	55.5 %	6	54.5 %	8	61.5 %	6	66.6 %	48	64.0 %
4 Resting Symptoms	1	4.3 %	1	10.0 %	1	7.6 %	2	22.2 %	5	6.6 %
5 Exertion Intolerant
6 Exertion Limited
7 Advanced NYHA Class 3
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	11	100.0 %	13	100.0 %	9	100.0 %	75	100.0 %

PRE-IMPLANT PATIENT PROFILE	STS InterMACS													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
1 Critical Cardiogenic Shock	101	13.1 %	82	14.9 %	88	12.9 %	50	9.3 %	65	11.6 %	68	12.9 %	454	12.5 %
2 Progressive Decline	250	32.5 %	185	33.6 %	212	31.1 %	171	31.9 %	190	33.9 %	160	30.4 %	1168	32.2 %
3 Stable but Inotrope Dependent	332	43.2 %	212	38.5 %	298	43.7 %	221	41.2 %	214	38.2 %	217	41.2 %	1494	41.2 %
4 Resting Symptoms	76	9.8 %	61	11.0 %	73	10.7 %	84	15.6 %	76	13.5 %	69	13.1 %	439	12.1 %
5 Exertion Intolerant	4	0.5 %	6	1.0 %	9	1.3 %	7	1.3 %	9	1.6 %	8	1.5 %	43	1.1 %
6 Exertion Limited	2	0.2 %	1	0.1 %	1	0.1 %	3	0.5 %	1	0.1 %	.	.	8	0.2 %
7 Advanced NYHA Class 3	3	0.3 %	3	0.5 %	5	0.8 %	4	0.7 %	15	0.4 %
TOTAL	768	100.0 %	550	100.0 %	681	100.0 %	536	100.0 %	560	100.0 %	526	100.0 %	3621	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9a. Medications - IV Inotropes Within 48 Hours of Implant

The following tables summarize IV inotrope therapy within 48 hours prior to implant at your site and STS Intermacs over time.

IV INOTROPES	HOSPX-9999																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Dobutamine	19	12	63.2%	10	4	40.0%	8	3	37.5%	9	3	33.3%	11	6	54.5%	7	3	42.9%
Dopamine	19	0	0.0%	10	0	0.0%	8	0	0.0%	9	0	0.0%	11	0	0.0%	7	0	0.0%
Milrinone	19	10	52.6%	10	9	90.0%	8	8	100.0%	9	7	77.8%	11	7	63.6%	7	7	100.0%
Levosimendan	19	1	5.3%	10	0	0.0%	8	0	0.0%	9	0	0.0%	11	0	0.0%	7	0	0.0%
Epinephrine	19	0	0.0%	10	0	0.0%	8	0	0.0%	9	1	11.1%	11	1	9.1%	7	0	0.0%
Norepinephrine	19	2	10.5%	10	0	0.0%	8	0	0.0%	9	1	11.1%	11	0	0.0%	7	0	0.0%
Isoproterenol	19	0	0.0%	10	0	0.0%	8	0	0.0%	9	0	0.0%	11	0	0.0%	7	0	0.0%
Other Specify	19	0	0.0%	10	1	10.0%	8	0	0.0%	9	0	0.0%	11	0	0.0%	7	0	0.0%
Unknown	19	2	10.5%	10	0	0.0%	8	0	0.0%	9	0	0.0%	11	0	0.0%	7	0	0.0%

IV INOTROPES	STS Intermacs																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Dobutamine	658	240	36.5%	467	173	37.0%	581	202	34.8%	434	170	39.2%	457	177	38.7%	425	150	35.3%
Dopamine	658	27	4.1%	467	16	3.4%	581	16	2.8%	434	20	4.6%	457	13	2.8%	425	24	5.6%
Milrinone	658	504	76.6%	467	365	78.2%	581	456	78.5%	434	330	76.0%	457	346	75.7%	425	321	75.5%
Levosimendan	658	1	0.2%	467	0	0.0%	581	0	0.0%	434	1	0.2%	457	1	0.2%	425	0	0.0%
Epinephrine	658	65	9.9%	467	37	7.9%	581	26	4.5%	434	29	6.7%	457	41	9.0%	425	31	7.3%
Norepinephrine	658	66	10.0%	467	28	6.0%	581	31	5.3%	434	20	4.6%	457	22	4.8%	425	27	6.4%
Isoproterenol	658	2	0.3%	467	0	0.0%	581	0	0.0%	434	0	0.0%	457	0	0.0%	425	0	0.0%
Other Specify	658	9	1.4%	467	4	0.9%	581	4	0.7%	434	1	0.2%	457	2	0.4%	425	4	0.9%
Unknown	658	2	0.3%	467	0	0.0%	581	0	0.0%	434	0	0.0%	457	1	0.2%	425	3	0.7%

IV INOTROPES	HOSPX-9999			STS Intermacs		
	N	Yes	%	N	Yes	%
Dobutamine	64	31	48.4%	3022	1112	36.8%
Dopamine	64	0	0.0%	3022	116	3.8%
Milrinone	64	48	75.0%	3022	2322	76.8%
Levosimendan	64	1	1.6%	3022	3	0.1%
Epinephrine	64	2	3.1%	3022	229	7.6%
Norepinephrine	64	3	4.7%	3022	194	6.4%
Isoproterenol	64	0	0.0%	3022	2	0.1%

(Continued)

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9a. Medications - IV Inotropes Within 48 Hours of Implant

IV INOTROPES	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Other Specify	64	1	1.6%	3022	24	0.8%
Unknown	64	2	3.1%	3022	6	0.2%

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9b. Medications - History and Current Use

The following tables compare the history and current use of specific medications prior to implant at your site and STS InterMACS.

ACE INHIBITORS	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	5	9.3	222	8.1
Known previous use (within past year)	9	16.7	574	21.0
No	24	44.4	1666	60.8
Unknown	16	29.6	277	10.1
TOTAL	54	100	2739	100

ALDOSTERONE ANTAGONIST	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	19	35.2	957	34.9
Known previous use (within past year)	17	31.5	662	24.2
No	10	18.5	950	34.7
Unknown	8	14.8	170	6.2
TOTAL	54	100	2739	100

ALLOPURINOL*	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	7	13.0	335	12.2
Known previous use (within past year)	3	5.6	146	5.3
No	26	48.1	1978	72.2
Unknown	18	33.3	280	10.2
TOTAL	54	100	2739	100

AMIODARONE	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	16	29.6	1027	37.5
Known previous use (within past year)	7	13.0	232	8.5
No	22	40.7	1302	47.5
Unknown	9	16.7	178	6.5
TOTAL	54	100	2739	100

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9b. Medications - History and Current Use

ANGIOTENSIN RECEPTOR BLOCKER	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	3	5.6	392	14.3
Known previous use (within past year)	15	27.8	720	26.3
No	20	37.0	1381	50.4
Unknown	16	29.6	246	9.0
TOTAL	54	100	2739	100

ANTIPLATELET THERAPY DRUG	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	25	46.3	1471	53.7
Known previous use (within past year)	13	24.1	475	17.3
No	11	20.4	671	24.5
Unknown	5	9.3	122	4.5
TOTAL	54	100	2739	100

BETA BLOCKERS	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	17	31.5	948	34.6
Known previous use (within past year)	23	42.6	1100	40.2
No	10	18.5	577	21.1
Unknown	4	7.4	114	4.2
TOTAL	54	100	2739	100

WARFARIN (COUMADIN)	HOSPX-9999		STS InterMACS	
	N	%	N	%
Currently using	.	.	223	8.1
Known previous use (within past year)	3	5.6	336	12.3
No	39	72.2	1936	70.7
Unknown	12	22.2	244	8.9
TOTAL	54	100	2739	100

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9b. Medications - History and Current Use

NESIRITIDE	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	39	90.7	2033	93.9
Unknown	4	9.3	128	5.9
Yes	.	.	3	0.1
TOTAL	43	100	2164	100

NITRIC OXIDE	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	46	85.2	2418	88.3
Unknown	7	13.0	149	5.4
Yes	1	1.9	172	6.3
TOTAL	54	100	2739	100

LOOP DIURETICS	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	7	13.0	384	14.0
Unknown	6	11.1	32	1.2
Yes	41	75.9	2323	84.8
TOTAL	54	100	2739	100

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 9b. Medications - History and Current Use

PRE-IMPLANT LOOP DIURETIC TYPE*	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Furosemide	39	19	48.72%	2274	1083	47.63%
Torsemide	39	14	35.90%	2274	661	29.07%
Bumetanide	39	6	15.38%	2274	561	24.67%
Other	39	0	0.00%	2274	5	0.22%

CARDIAC RESYNCHRONIZATION THERAPY (CRT)*	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	20	46.5	1447	67.2
Unknown	6	14.0	97	4.5
Yes	17	39.5	608	28.3
TOTAL	43	100	2152	100

METALAZONE / THIAZIDE*	HOSPX-9999		STS InterMACS	
	N	%	N	%
No	34	63.0	2255	82.3
Unknown	17	31.5	128	4.7
Yes	3	5.6	356	13.0
TOTAL	54	100	2739	100

METALAZONE / THIAZIDE - FREQUENCY*	HOSPX-9999		STS InterMACS	
	N	%	N	%
Regular	2	66.7	158	44.4
Intermittent	1	33.3	198	55.6
TOTAL	3	100	356	100

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 10. Laboratories

The following tables summarize pre-implant laboratories at your site and STS InterMACS.

		HOSPX-9999	STS InterMACS
Sodium (mEq/L)	N	54	2737
	Mean	133.31	135.07
	Std	4.93	4.46
	Min	122.00	116.00
	Max	142.00	156.00
Potassium (mEq/L)	N	54	2737
	Mean	4.19	4.06
	Std	0.55	0.44
	Min	3.00	2.50
	Max	5.50	6.50
BUN (mg/dL)	N	54	2725
	Mean	37.78	28.71
	Std	43.82	17.21
	Min	11.00	1.30
	Max	336.00	336.00
Creatinine (mg/dL)	N	54	2737
	Mean	1.62	1.37
	Std	1.38	0.71
	Min	0.70	0.38
	Max	9.00	14.82
Alanine Aminotransferase/ALT (u/L)	N	52	2691
	Mean	39.04	49.23
	Std	30.33	99.45
	Min	9.00	4.00
	Max	139.00	1700.00
Aspartate Aminotransferase/AST (u/L)	N	52	2690
	Mean	40.35	42.00
	Std	44.39	103.64
	Min	11.00	4.00
	Max	273.00	3996.00
LDH (μkat/L), (U/L)	N	38	1871
	Mean	485.37	358.91
	Std	419.15	322.35
	Min	218.00	10.00
	Max	2560.00	6234.00
All	N	75	3621

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 10. Laboratories

PRE-IMPLANT LABORATORIES		HOSPX-9999	STS Intermacs
Total Bilirubin (mg/dL)	N	52	2695
	Mean	1.36	1.19
	Std	1.41	1.11
	Min	0.20	0.10
	Max	8.00	19.70
Albumin (g/dL)	N	52	2682
	Mean	3.57	3.50
	Std	0.42	0.58
	Min	2.70	0.25
	Max	4.70	7.50
Pre-albumin (mg/dL)	N	41	1639
	Mean	17.59	18.51
	Std	7.32	6.97
	Min	7.00	3.00
	Max	41.90	49.60
Total Cholesterol (mg/dL)	N	45	1813
	Mean	130.73	127.49
	Std	55.05	40.15
	Min	60.00	50.00
	Max	410.00	410.00
Brain Natriuretic Peptide (pg/mL)	N	8	1223
	Mean	2133.00	1352.15
	Std	1538.58	1239.50
	Min	287.00	1.00
	Max	4253.00	7500.00
Pro Brain Natriuretic Peptide (pg/mL)	N	40	1179
	Mean	5604.88	6447.15
	Std	4735.19	7483.72
	Min	100.00	68.00
	Max	18430.00	60000.00
White Blood Cell Count (x10/ μ L)	N	54	2736
	Mean	9.31	8.50
	Std	3.32	3.82
	Min	4.16	2.30
	Max	18.43	67.40
Hemoglobin (g/dL)	N	54	2735
	Mean	10.72	11.22
	Std	2.56	2.14
	Min	4.26	0.77
	Max	15.60	18.80
All	N	75	3621

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Clinical Characteristics

Exhibit 10. Laboratories

PRE-IMPLANT LABORATORIES		HOSPX-9999	STS InterMACs
Platelets (x10/ μ L)	N	54	2733
	Mean	225.31	201.83
	Std	89.79	85.01
	Min	47.00	4.00
	Max	505.00	800.00
INR	N	53	2620
	Mean	1.28	1.25
	Std	0.36	0.28
	Min	0.99	0.79
	Max	2.60	4.50
Sensitivity CRP (mg/L)	N	13	974
	Mean	58.27	23.01
	Std	91.11	49.15
	Min	1.20	0.02
	Max	300.00	697.00
All	N	75	3621

PRE-IMPLANT LUPUS ANTICOAGULANT STATUS*	HOSPX-9999		STS InterMACs	
	N	%	N	%
Negative	.	.	336	12.3
Positive	.	.	35	1.3
Unknown	54	100	2367	86.4
TOTAL	54	100	2738	100

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant****Exhibit 11. Pre-Implant Comorbidities**

The following tables compares pre-implant comorbidities at the time of durable MCSD implant between your site and STS InterMACs over time. This section was revised during the v6.0 launch (11/24/20) and includes mapped data from patients implanted 2012 and later. Information on Prior Sternotomy and History of Hematopoietic Cancer is currently being mapped and will be available in the reports starting next quarter.

Cardiothoracic issues	HOSPX-9999																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Frequent ICD Shocks	23	0	0.0%	10	0	0.0%	9	0	0.0%	6	1	16.7%	0	.	.	0	.	.
Chronic Lung Disease	23	5	21.7%	10	0	0.0%	9	0	0.0%	7	0	0.0%	2	2	100.0%	0	.	.
Pulmonary Hypertension	23	6	26.1%	10	0	0.0%	9	0	0.0%	8	2	25.0%	1	1	100.0%	0	.	.
Recent Pulmonary Embolus	23	0	0.0%	10	0	0.0%	9	1	11.1%	8	0	0.0%	2	0	0.0%	0	.	.
History of Atrial Arrhythmia	23	4	17.4%	10	0	0.0%	9	1	11.1%	6	1	16.7%	1	1	100.0%	0	.	.
Thoracic Aortic Disease	22	1	4.5%	10	0	0.0%	9	0	0.0%	8	1	12.5%	1	1	100.0%	0	.	.

Cardiothoracic issues	STS InterMACs																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Frequent ICD Shocks	767	32	4.2%	545	33	6.1%	667	22	3.3%	506	19	3.8%	229	8	3.5%	0	.	.
Chronic Lung Disease	767	62	8.1%	545	52	9.5%	668	61	9.1%	506	95	18.8%	229	70	30.6%	0	.	.
Pulmonary Hypertension	767	140	18.3%	545	88	16.1%	669	129	19.3%	504	182	36.1%	230	106	46.1%	0	.	.
Recent Pulmonary Embolus	767	11	1.4%	545	7	1.3%	669	15	2.2%	514	8	1.6%	238	4	1.7%	0	.	.
History of Atrial Arrhythmia	767	142	18.5%	545	93	17.1%	669	115	17.2%	510	171	33.5%	232	111	47.8%	0	.	.
Thoracic Aortic Disease	766	5	0.7%	545	3	0.6%	669	3	0.4%	510	7	1.4%	233	2	0.9%	0	.	.

Cardiothoracic issues	HOSPX-9999			STS InterMACs		
	N	Yes	%	N	Yes	%
Frequent ICD Shocks	48	1	2.1%	2714	114	4.2%
Chronic Lung Disease	51	7	13.7%	2715	340	12.5%
Pulmonary Hypertension	51	9	17.6%	2715	645	23.8%
Recent Pulmonary Embolus	52	1	1.9%	2733	45	1.6%
History of Atrial Arrhythmia	49	7	14.3%	2723	632	23.2%
Thoracic Aortic Disease	50	3	6.0%	2723	20	0.7%

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Nutritional/GI issues	HOSPX-9999																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Severe Diabetes	23	5	21.7%	10	0	0.0%	9	0	0.0%	9	2	22.2%	3	1	33.3%	0	.	.
Malnutrition/Cachexia	23	1	4.3%	10	0	0.0%	9	0	0.0%	9	0	0.0%	2	2	100.0%	0	.	.
History GI Ulcers	22	0	0.0%	10	0	0.0%	9	0	0.0%	7	0	0.0%	0	.	.	0	.	.
Liver Dysfunction	23	1	4.3%	10	0	0.0%	9	0	0.0%	6	1	16.7%	0	.	.	0	.	.
Hepatitis	23	0	0.0%	10	0	0.0%	9	0	0.0%	7	0	0.0%	2	0	0.0%	0	.	.

Nutritional/GI issues	STS InterMACS																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Severe Diabetes	767	97	12.6%	545	57	10.5%	669	69	10.3%	517	63	12.2%	240	45	18.8%	0	.	.
Malnutrition/Cachexia	767	21	2.7%	545	15	2.8%	667	12	1.8%	514	35	6.8%	231	17	7.4%	0	.	.
History GI Ulcers	766	4	0.5%	545	2	0.4%	669	2	0.3%	511	12	2.3%	234	5	2.1%	0	.	.
Liver Dysfunction	767	24	3.1%	545	20	3.7%	668	19	2.8%	511	31	6.1%	233	17	7.3%	0	.	.
Hepatitis	767	9	1.2%	545	10	1.8%	669	3	0.4%	510	7	1.4%	232	7	3.0%	0	.	.

Nutritional/GI issues	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Severe Diabetes	54	8	14.8%	2738	331	12.1%
Malnutrition/Cachexia	53	3	5.7%	2724	100	3.7%
History GI Ulcers	48	0	0.0%	2725	25	0.9%
Liver Dysfunction	48	2	4.2%	2724	111	4.1%
Hepatitis	51	0	0.0%	2723	36	1.3%

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Vascular issues	HOSPX-9999																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Heparin-induced Thrombocytopenia	22	1	4.5%	10	0	0.0%	9	0	0.0%	7	1	14.3%	1	0	0.0%	0	.	.
Chronic Coagulopathy	22	0	0.0%	10	0	0.0%	9	0	0.0%	7	0	0.0%	0	.	.	0	.	.
Cerebrovascular Disease	22	2	9.1%	10	0	0.0%	9	0	0.0%	9	0	0.0%	2	0	0.0%	0	.	.
Major Stroke	22	2	9.1%	9	0	0.0%	9	0	0.0%	2	0	0.0%	0	.	.	0	.	.
Peripheral Arterial Disease	23	1	4.3%	10	0	0.0%	9	0	0.0%	9	0	0.0%	2	2	100.0%	0	.	.

Vascular issues	STS Intermacs																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Heparin-induced Thrombocytopenia	766	7	0.9%	545	8	1.5%	667	10	1.5%	506	4	0.8%	229	9	3.9%	0	.	.
Chronic Coagulopathy	766	4	0.5%	545	5	0.9%	668	12	1.8%	509	9	1.8%	230	3	1.3%	0	.	.
Cerebrovascular Disease	766	41	5.4%	545	28	5.1%	668	34	5.1%	513	40	7.8%	238	41	17.2%	0	.	.
Major Stroke	760	25	3.3%	534	17	3.2%	621	22	3.5%	263	32	12.2%	39	29	74.4%	0	.	.
Peripheral Arterial Disease	767	33	4.3%	545	21	3.9%	668	31	4.6%	512	32	6.3%	233	22	9.4%	0	.	.

Vascular issues	HOSPX-9999			STS Intermacs		
	N	Yes	%	N	Yes	%
Heparin-induced Thrombocytopenia	49	2	4.1%	2713	38	1.4%
Chronic Coagulopathy	48	0	0.0%	2718	33	1.2%
Cerebrovascular Disease	52	2	3.8%	2730	184	6.7%
Major Stroke	42	2	4.8%	2217	125	5.6%
Peripheral Arterial Disease	53	3	5.7%	2725	139	5.1%

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Oncology/infection issues	HOSPX-9999																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
History Solid Organ Cancer	23	0	0.0%	10	0	0.0%	9	1	11.1%	9	0	0.0%	2	0	0.0%	0	.	.
Currently has Cancer v6	1	0	0.0%	0	.	.	0	.	.	6	0	0.0%	2	0	0.0%	0	.	.
History of Solid Organ Transplant v6	1	0	0.0%	0	.	.	0	.	.	7	0	0.0%	3	0	0.0%	0	.	.
History of Bone Marrow Transplant (BMT)	23	0	0.0%	10	0	0.0%	9	0	0.0%	9	0	0.0%	3	0	0.0%	0	.	.
HIV	22	0	0.0%	10	0	0.0%	9	0	0.0%	2	0	0.0%	0	.	.	0	.	.

Oncology/infection issues	STS InterMACS																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
History Solid Organ Cancer	767	44	5.7%	545	21	3.9%	669	36	5.4%	516	32	6.2%	240	20	8.3%	0	.	.
Currently has Cancer v6	8	0	0.0%	10	0	0.0%	52	1	1.9%	278	4	1.4%	233	5	2.1%	0	.	.
History of Solid Organ Transplant v6	8	0	0.0%	10	0	0.0%	53	0	0.0%	282	1	0.4%	241	3	1.2%	0	.	.
History of Bone Marrow Transplant (BMT)	767	0	0.0%	545	1	0.2%	669	0	0.0%	514	3	0.6%	238	1	0.4%	0	.	.
HIV	762	7	0.9%	537	2	0.4%	619	5	0.8%	243	1	0.4%	0	.	.	0	.	.

Oncology/infection issues	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
History Solid Organ Cancer	53	1	1.9%	2737	153	5.6%
Currently has Cancer v6	9	0	0.0%	581	10	1.7%
History of Solid Organ Transplant v6	11	0	0.0%	594	4	0.7%
History of Bone Marrow Transplant (BMT)	54	0	0.0%	2733	5	0.2%
HIV	43	0	0.0%	2161	15	0.7%

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 11. Pre-Implant Comorbidities

Data collection for the psychosocial issues section changed structure as a part of the v6.0 release. Mapping of this data is underway and this information will be available in the reports starting next quarter.

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 12. Pre-Implant Potential Barriers to Heart Transplant

The following tables compare pre-implant potential barriers to heart transplant at your site and STS Intermacs over time. This section was revised during the v6.0 launch (11/24/20) and includes mapped data from patients implanted 2012 and later.

Potential Barriers to Heart Transplant	HOSPX-9999																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Advanced Age	23	4	17.4%	10	0	0.0%	9	0	0.0%	9	0	0.0%	3	0	0.0%	0	.	.
Frailty	23	0	0.0%	10	0	0.0%	9	0	0.0%	8	0	0.0%	2	1	50.0%	0	.	.
Patient Does Not Want Transplant	23	1	4.3%	10	0	0.0%	9	0	0.0%	6	0	0.0%	2	0	0.0%	0	.	.
Musculoskeletal Limitation to Ambulation	23	0	0.0%	10	0	0.0%	9	0	0.0%	8	0	0.0%	2	0	0.0%	0	.	.
Contraindications to Immunosuppression	23	0	0.0%	10	0	0.0%	9	0	0.0%	7	0	0.0%	2	0	0.0%	0	.	.
Allosensitization	23	1	4.3%	10	0	0.0%	9	0	0.0%	7	0	0.0%	1	1	100.0%	0	.	.
Chronic Renal Disease	23	1	4.3%	10	0	0.0%	9	0	0.0%	7	0	0.0%	2	1	50.0%	0	.	.
Large BMI	23	6	26.1%	10	2	20.0%	9	0	0.0%	9	1	11.1%	3	0	0.0%	0	.	.
Chronic Infectious Concerns	23	0	0.0%	10	0	0.0%	9	0	0.0%	6	0	0.0%	1	0	0.0%	0	.	.

Potential Barriers to Heart Transplant	STS Intermacs																	
	2020 Q1			2020 Q2			2020 Q3			2020 Q4			2021 Q1			2021 Q2		
	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%	N	Yes	%
Advanced Age	767	145	18.9%	545	96	17.6%	667	118	17.7%	505	102	20.2%	234	41	17.5%	0	.	.
Frailty	767	46	6.0%	545	29	5.3%	667	34	5.1%	498	31	6.2%	229	19	8.3%	0	.	.
Patient Does Not Want Transplant	767	15	2.0%	545	14	2.6%	665	20	3.0%	478	9	1.9%	195	7	3.6%	0	.	.
Musculoskeletal Limitation to Ambulation	767	6	0.8%	545	3	0.6%	667	1	0.1%	504	4	0.8%	222	4	1.8%	0	.	.
Contraindications to Immunosuppression	767	2	0.3%	545	0	0.0%	667	3	0.4%	496	6	1.2%	216	3	1.4%	0	.	.
Allosensitization	767	8	1.0%	545	4	0.7%	666	8	1.2%	489	9	1.8%	204	2	1.0%	0	.	.
Chronic Renal Disease	767	55	7.2%	545	31	5.7%	666	59	8.9%	502	75	14.9%	228	61	26.8%	0	.	.
Large BMI	767	131	17.1%	545	81	14.9%	668	116	17.4%	505	117	23.2%	233	65	27.9%	0	.	.
Chronic Infectious Concerns	767	4	0.5%	545	5	0.9%	667	6	0.9%	501	6	1.2%	224	4	1.8%	0	.	.

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Comorbidities and Potential Barriers to Heart Transplant

Exhibit 12. Pre-Implant Potential Barriers to Heart Transplant

Potential Barriers to Heart Transplant	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
Advanced Age	54	4	7.4%	2718	502	18.5%
Frailty	52	1	1.9%	2706	159	5.9%
Patient Does Not Want Transplant	50	1	2.0%	2650	65	2.5%
Musculoskeletal Limitation to Ambulation	52	0	0.0%	2705	18	0.7%
Contraindications to Immunosuppression	51	0	0.0%	2691	14	0.5%
Allosensitization	50	2	4.0%	2671	31	1.2%
Chronic Renal Disease	51	2	3.9%	2708	281	10.4%
Large BMI	54	9	16.7%	2718	510	18.8%
Chronic Infectious Concerns	49	0	0.0%	2704	25	0.9%

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 13. General Hemodynamics

The following table summarizes pre-implant heart rate, systolic BP and diastolic BP at your site and STS InterMACS.

PRE-IMPLANT GENERAL HEMODYNAMICS		HOSPX-9999	STS InterMACS
Heart Rate	N	54	2734
	Mean	95.54	91.56
	Std	20.74	17.62
	Min	68.00	40.00
	Max	175.00	175.00
Diastolic Blood Pressure (mmHg)	N	53	2702
	Mean	66.60	68.32
	Std	11.69	11.81
	Min	42.00	26.00
	Max	90.00	120.00
Systolic Blood Pressure (mmHg)	N	53	2705
	Mean	108.62	108.90
	Std	15.71	16.43
	Min	70.00	56.00
	Max	145.00	183.00
All	N	75	3621

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 14a. Echo Hemodynamics - LVEDD**

The following tables summarizes pre-implant LVEDD at your site and STS Intermacs over time.

GROUP=HOSPX-9999

PRE-IMPLANT LVEDD (cm)		2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	TOTAL
	N	22	9	8	8	2	0	49
	Mean	6.81	6.89	6.78	6.51	7.12	.	6.78
	Std	0.78	1.26	1.51	0.86	0.11	.	0.99
	Min	5.40	4.44	5.00	5.05	7.04	.	4.44
	Max	8.40	8.52	9.50	7.60	7.19	.	9.50

GROUP=STS Intermacs

PRE-IMPLANT LVEDD (cm)		2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	TOTAL
	N	613	453	554	441	194	0	2255
	Mean	6.80	6.71	6.83	6.82	6.86	.	6.80
	Std	1.06	1.08	1.10	1.02	0.93	.	1.06
	Min	3.60	2.02	3.18	4.00	4.90	.	2.02
	Max	11.50	10.20	11.00	10.57	9.80	.	11.50

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 14b. Echo Hemodynamics - LVEF

The following tables summarizes pre-implant LVEF at your site and STS Intermacs over time.

PRE-IMPLANT LVEF	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
> 50 (normal)
40-49 (mild)
30-39 (moderate)
20-29 (moderate/severe)	3	13.0 %	3	30.0 %	2	22.2 %	1	11.1 %	1	33.3 %	10	18.5 %
< 20 (severe)	20	86.9 %	7	70.0 %	7	77.7 %	7	77.7 %	2	66.6 %	43	79.6 %
Not Recorded or Not Documented	1	11.1 %	.	.	1	1.8 %
Unknown
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	9	100.0 %	3	100.0 %	54	100.0 %

PRE-IMPLANT LVEF	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
> 50 (normal)	2	0.2 %	1	0.1 %	1	0.1 %	2	0.3 %	1	0.4 %	7	0.2 %
40-49 (mild)	2	0.2 %	2	0.3 %	2	0.2 %	1	0.1 %	1	0.4 %	8	0.2 %
30-39 (moderate)	16	2.0 %	13	2.3 %	25	3.7 %	12	2.3 %	5	2.0 %	71	2.5 %
20-29 (moderate/severe)	194	25.2 %	142	26.0 %	177	26.4 %	128	24.7 %	77	31.9 %	718	26.2 %
< 20 (severe)	516	67.2 %	358	65.6 %	440	65.7 %	356	68.8 %	142	58.9 %	1812	66.1 %
Not Recorded or Not Documented	33	4.3 %	29	5.3 %	24	3.5 %	15	2.9 %	14	5.8 %	115	4.1 %
Unknown	4	0.5 %	3	0.5 %	1	0.4 %	8	0.2 %
TOTAL	767	100.0 %	545	100.0 %	669	100.0 %	517	100.0 %	241	100.0 %	2739	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 14c. Echo Hemodynamics - RVEF

The following tables summarizes pre-implant RVEF at your site and STS Intermacs over time.

PRE-IMPLANT RVEF	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Normal	8	34.7 %	2	20.0 %	2	22.2 %	2	22.2 %	.	.	14	25.9 %
Mild	5	21.7 %	5	50.0 %	1	11.1 %	2	22.2 %	2	66.6 %	15	27.7 %
Moderate	7	30.4 %	.	.	5	55.5 %	3	33.3 %	1	33.3 %	16	29.6 %
Severe	1	4.3 %	2	20.0 %	.	.	1	11.1 %	.	.	4	7.4 %
Not Done	1	4.3 %	1	1.8 %
Not Applicable (v4)	1	11.1 %	.	.	1	1.8 %
Unknown	1	4.3 %	1	10.0 %	1	11.1 %	3	5.5 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	9	100.0 %	3	100.0 %	54	100.0 %

PRE-IMPLANT RVEF	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Normal	166	21.6 %	128	23.4 %	158	23.6 %	109	21.0 %	56	23.2 %	617	22.5 %
Mild	205	26.7 %	123	22.5 %	165	24.6 %	131	25.3 %	55	22.8 %	679	24.7 %
Moderate	194	25.2 %	146	26.7 %	169	25.2 %	131	25.3 %	53	21.9 %	693	25.3 %
Severe	90	11.7 %	61	11.1 %	68	10.1 %	60	11.6 %	29	12.0 %	308	11.2 %
Not Done	66	8.6 %	58	10.6 %	61	9.1 %	45	8.7 %	23	9.5 %	253	9.2 %
Not Applicable (v4)	1	0.1 %	1	0.1 %	.	.	3	0.5 %	1	0.4 %	6	0.2 %
Unknown	45	5.8 %	28	5.1 %	48	7.1 %	38	7.3 %	24	9.9 %	183	6.6 %
TOTAL	767	100.0 %	545	100.0 %	669	100.0 %	517	100.0 %	241	100.0 %	2739	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 14d. Echo Hemodynamics - Mitral Regurgitation

The following tables summarizes pre-implant mitral regurgitation at your site and STS Intermacs over time.

PRE-IMPLANT MITRAL REGURGITATION	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	1	4.3 %	2	20.0 %	.	.	1	11.1 %	1	33.3 %	5	9.2 %
1 (mild)	11	47.8 %	3	30.0 %	3	33.3 %	2	22.2 %	.	.	19	35.1 %
2 (moderate)	5	21.7 %	2	20.0 %	4	44.4 %	3	33.3 %	1	33.3 %	15	27.7 %
3 (severe)	6	26.0 %	2	20.0 %	2	22.2 %	3	33.3 %	.	.	13	24.0 %
Not Recorded or Not Documented	.	.	1	10.0 %	1	33.3 %	2	3.7 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	9	100.0 %	3	100.0 %	54	100.0 %

PRE-IMPLANT MITRAL REGURGITATION	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	71	9.2 %	46	8.4 %	48	7.1 %	39	7.5 %	15	6.2 %	219	7.9 %
1 (mild)	232	30.2 %	178	32.6 %	229	34.2 %	179	34.6 %	88	36.5 %	906	33.0 %
2 (moderate)	236	30.7 %	169	31.0 %	221	33.0 %	157	30.3 %	70	29.0 %	853	31.1 %
3 (severe)	162	21.1 %	113	20.7 %	134	20.0 %	111	21.4 %	48	19.9 %	568	20.7 %
Not Recorded or Not Documented	66	8.6 %	39	7.1 %	37	5.5 %	31	5.9 %	20	8.2 %	193	7.0 %
TOTAL	767	100.0 %	545	100.0 %	669	100.0 %	517	100.0 %	241	100.0 %	2739	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 14e. Echo Hemodynamics - Aortic Regurgitation**

The following tables summarizes pre-implant aortic regurgitation at your site and STS Intermacs over time.

PRE-IMPLANT AORTIC REGURGITATION	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	8	34.7 %	2	20.0 %	2	22.2 %	2	22.2 %	.	.	14	25.9 %
1 (mild)	9	39.1 %	1	10.0 %	2	22.2 %	1	11.1 %	2	66.6 %	15	27.7 %
2 (moderate)	1	4.3 %	.	.	1	11.1 %	2	3.7 %
3 (severe)	.	.	1	10.0 %	1	1.8 %
Not Recorded or Not Documented	5	21.7 %	6	60.0 %	4	44.4 %	6	66.6 %	1	33.3 %	22	40.7 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	9	100.0 %	3	100.0 %	54	100.0 %

PRE-IMPLANT AORTIC REGURGITATION	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	425	55.4 %	304	55.7 %	367	54.8 %	286	55.3 %	135	56.0 %	1517	55.3 %
1 (mild)	215	28.0 %	140	25.6 %	197	29.4 %	160	30.9 %	62	25.7 %	774	28.2 %
2 (moderate)	23	2.9 %	23	4.2 %	24	3.5 %	13	2.5 %	11	4.5 %	94	3.4 %
3 (severe)	6	0.7 %	3	0.5 %	7	1.0 %	2	0.3 %	1	0.4 %	19	0.6 %
Not Recorded or Not Documented	98	12.7 %	75	13.7 %	74	11.0 %	56	10.8 %	32	13.2 %	335	12.2 %
TOTAL	767	100.0 %	545	100.0 %	669	100.0 %	517	100.0 %	241	100.0 %	2739	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 14f. Echo Hemodynamics - Tricuspid Regurgitation

The following tables summarizes pre-implant tricuspid regurgitation at your site and STS Intermacs over time.

PRE-IMPLANT TRICUSPID REGURGITATION	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	4	17.3 %	1	10.0 %	2	22.2 %	7	12.9 %
1 (mild)	9	39.1 %	6	60.0 %	5	55.5 %	4	44.4 %	2	66.6 %	26	48.1 %
2 (moderate)	9	39.1 %	2	20.0 %	1	11.1 %	3	33.3 %	1	33.3 %	16	29.6 %
3 (severe)	1	4.3 %	.	.	1	11.1 %	1	11.1 %	.	.	3	5.5 %
Not Recorded or Not Documented	.	.	1	10.0 %	.	.	1	11.1 %	.	.	2	3.7 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	9	100.0 %	3	100.0 %	54	100.0 %

PRE-IMPLANT TRICUSPID REGURGITATION	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
0 (none)	76	9.9 %	51	9.3 %	67	10.0 %	47	9.0 %	16	6.6 %	257	9.3 %
1 (mild)	330	43.0 %	248	45.5 %	309	46.1 %	225	43.5 %	111	46.0 %	1223	44.6 %
2 (moderate)	236	30.7 %	137	25.1 %	172	25.7 %	152	29.4 %	66	27.3 %	763	27.8 %
3 (severe)	65	8.4 %	65	11.9 %	76	11.3 %	59	11.4 %	26	10.7 %	291	10.6 %
Not Recorded or Not Documented	60	7.8 %	44	8.0 %	45	6.7 %	34	6.5 %	22	9.1 %	205	7.4 %
TOTAL	767	100.0 %	545	100.0 %	669	100.0 %	517	100.0 %	241	100.0 %	2739	100.0 %

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Hemodynamics

Exhibit 15. Swan Hemodynamics

The following table summarizes pre-implant hemodynamics derived from a Swan-Ganz catheter at your site and STS InterMACS.

PRE-IMPLANT SWAN HEMODYNAMICS		HOSPX-9999	STS InterMACS
Pulmonary Artery Systolic Pressure (mmHg)	N	53	2485
	Mean	48.94	49.43
	Std	13.21	14.85
	Min	20.00	7.00
	Max	85.00	100.00
Pulmonary Artery Diastolic Pressure (mmHg)	N	53	2475
	Mean	25.00	24.80
	Std	8.99	8.86
	Min	6.00	0.00
	Max	53.00	60.00
~Mean RA Pressure (mmHg)~	N	38	1595
	Mean	22.03	12.21
	Std	11.88	8.42
	Min	2.00	-3.00
	Max	40.00	55.00
Mean Pulmonary Artery Capillary Wedge Pressure (mmHg)	N	47	2077
	Mean	23.15	24.56
	Std	9.47	9.49
	Min	4.00	1.00
	Max	48.00	50.00
Cardiac Index	N	52	2374
	Mean	2.44	2.12
	Std	0.98	0.77
	Min	1.03	0.70
	Max	6.60	13.00
Cardiac Output (L/min)	N	50	2366
	Mean	4.63	4.25
	Std	2.02	1.45
	Min	1.40	0.60
	Max	13.10	13.10
All	N	75	3621

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Hemodynamics****Exhibit 16. ECG Cardiac Rhythm**

The following tables summarizes pre-implant ECG cardiac rhythm at your site and STS Intermacs.

ECG CARDIAC RHYTHM	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Sinus	10	43.4 %	7	70.0 %	2	22.2 %	7	77.7 %	2	66.6 %	28	51.8 %
Atrial fibrillation	4	17.3 %	1	10.0 %	.	.	1	11.1 %	.	.	6	11.1 %
Atrial Flutter	1	11.1 %	1	1.8 %
Not done
Atrial Paced, Ventricular Sensed	1	4.3 %	.	.	1	11.1 %	2	3.7 %
Atrial Sensed, Ventricular Paced	4	17.3 %	4	7.4 %
Atrial Paced, Ventricular Paced	2	8.6 %	.	.	4	44.4 %	6	11.1 %
Junctional (v6)
Unknown	1	4.3 %	1	11.1 %	.	.	2	3.7 %
Other, specify	1	4.3 %	2	20.0 %	1	11.1 %	.	.	1	33.3 %	5	9.2 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	9	100.0 %	3	100.0 %	54	100.0 %

ECG CARDIAC RHYTHM	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Sinus	410	53.4 %	300	55.0 %	369	55.1 %	295	57.0 %	135	56.0 %	1509	55.0 %
Atrial fibrillation	62	8.0 %	27	4.9 %	48	7.1 %	31	5.9 %	21	8.7 %	189	6.9 %
Atrial Flutter	4	0.5 %	5	0.9 %	9	1.3 %	6	1.1 %	1	0.4 %	25	0.9 %
Not done	7	0.9 %	3	0.5 %	8	1.1 %	5	0.9 %	.	.	23	0.8 %
Atrial Paced, Ventricular Sensed	15	1.9 %	11	2.0 %	20	2.9 %	6	1.1 %	3	1.2 %	55	2.0 %
Atrial Sensed, Ventricular Paced	133	17.3 %	101	18.5 %	103	15.3 %	80	15.4 %	36	14.9 %	453	16.5 %
Atrial Paced, Ventricular Paced	68	8.8 %	55	10.0 %	68	10.1 %	43	8.3 %	19	7.8 %	253	9.2 %
Junctional (v6)	1	0.1 %	.	.	1	0.0 %
Unknown	19	2.4 %	12	2.2 %	7	1.0 %	21	4.0 %	6	2.4 %	65	2.3 %
Other, specify	49	6.3 %	31	5.6 %	37	5.5 %	29	5.6 %	20	8.2 %	166	6.0 %
TOTAL	767	100.0 %	545	100.0 %	669	100.0 %	517	100.0 %	241	100.0 %	2739	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 17a. Functional Capacity - NYHA Class**

The following table summarizes the pre-implant NYHA Class at your site and STS Intermacs over time.

PRE-IMPLANT NYHA CLASS	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Class I
Class II
Class III	1	4.3 %	1	10.0 %	2	3.7 %
Class IV	22	95.6 %	9	90.0 %	9	100.0 %	9	100.0 %	2	66.6 %	51	94.4 %
Unknown	1	33.3 %	1	1.8 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	9	100.0 %	3	100.0 %	54	100.0 %

PRE-IMPLANT NYHA CLASS	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Class I	1	0.1 %	.	.	3	0.4 %	.	.	1	0.4 %	5	0.1 %
Class II	10	1.3 %	7	1.2 %	10	1.4 %	8	1.5 %	4	1.6 %	39	1.4 %
Class III	97	12.6 %	69	12.6 %	94	14.0 %	90	17.4 %	40	16.5 %	390	14.2 %
Class IV	651	84.8 %	462	84.7 %	554	82.8 %	408	78.9 %	193	80.0 %	2268	82.8 %
Unknown	8	1.0 %	7	1.2 %	8	1.1 %	11	2.1 %	3	1.2 %	37	1.3 %
TOTAL	767	100.0 %	545	100.0 %	669	100.0 %	517	100.0 %	241	100.0 %	2739	100.0 %

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 17b. Functional Capacity - VO2 Max

The following table summarizes the pre-implant VO2 max at your site and STS InterMACs.

VO2 MAX		HOSPX-9999	STS InterMACs
VO2 Max (mL/kg/min)	N	0	232
	Mean	.	16.16
	Std	.	64.13
	Min	.	0.90
	Max	.	978.00
All	N	75	3621

The following table summarizes the reasons the pre-implant VO2 max was incomplete at your site and STS InterMACs.

VO2 MAX - Reason for Incomplete	HOSPX-9999		STS InterMACs	
	N	%	N	%
Not Done: Other	39	72.2	1375	54.8
Not Done: Too Sick	12	22.2	840	33.5
Unknown	3	5.6	292	11.6
TOTAL	54	100	2507	100

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 17c. Functional Capacity - R Value at Peak

The following table summarizes the pre-implant R value at peak at your site and STS InterMACS.

R VALUE AT PEAK		HOSPX-9999	STS InterMACS
Peak R (%)	N	0	173
	Mean	.	8.46
	Std	.	15.73
	Min	.	0.72
	Max	.	78.00
All	N	75	3621

The following table summarizes the reasons the pre-implant R value at peak was incomplete at your site and InterMACS.

R VALUE AT PEAK - Reason for Incomplete	HOSPX-9999		STS InterMACS	
	N	%	N	%
Not Done	53	98.1	2253	87.8
Unknown	1	1.9	313	12.2
TOTAL	54	100	2566	100

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 17d. Functional Capacity - Six Minute Walk

The following table summarizes the pre-implant six minute walk at your site and STS InterMACS.

6 MINUTE WALK		HOSPX-9999	STS InterMACS
Six Minute Walk (ft)	N	4	568
	Mean	1122.50	848.82
	Std	238.10	515.51
	Min	900.00	0.00
	Max	1400.00	8268.00
All	N	75	3621

The following table summarizes the reasons the pre-implant six minute walk was incomplete at your site and STS InterMACS.

6 MINUTE WALK - Reason for Incomplete	HOSPX-9999		STS InterMACS	
	N	%	N	%
Not Done: Other	37	74.0	1020	47.0
Not Done: Too Sick	11	22.0	1035	47.7
Unknown	2	4.0	116	5.3
TOTAL	50	100	2171	100

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18a. Quality of Life - EQ-5D Mobility

The following table compares the EQ-5D Mobility domain between your site and STS InterMACS.

EQ-5D Mobility	HOSPX-9999									
	2020 Q1		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%
I have no problems in walking about	3	33.3 %	.	.	1	25.0 %	.	.	4	25.0 %
I have some problems in walking about	6	66.6 %	1	100.0 %	1	25.0 %	2	100.0 %	10	62.5 %
I am confined to bed	1	25.0 %	.	.	1	6.2 %
Unknown	1	25.0 %	.	.	1	6.2 %
TOTAL	9	100.0 %	1	100.0 %	4	100.0 %	2	100.0 %	16	100.0 %

EQ-5D Mobility	STS InterMACS											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
I have no problems in walking about	139	38.2 %	83	35.7 %	125	38.9 %	111	40.8 %	45	32.8 %	503	37.9 %
I have some problems in walking about	186	51.2 %	118	50.8 %	151	47.0 %	130	47.7 %	68	49.6 %	653	49.2 %
I am confined to bed	32	8.8 %	24	10.3 %	30	9.3 %	28	10.2 %	11	8.0 %	125	9.4 %
Unknown	6	1.6 %	7	3.0 %	15	4.6 %	3	1.1 %	13	9.4 %	44	3.3 %
TOTAL	363	100.0 %	232	100.0 %	321	100.0 %	272	100.0 %	137	100.0 %	1325	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18b. Quality of Life - EQ-5D Self Care

The following table compares the EQ-5D Self Care domain between your site and STS InterMACS.

EQ-5D Self Care	HOSPX-9999									
	2020 Q1		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%
I have no problems with self-care	6	66.6 %	1	100.0 %	2	50.0 %	2	100.0 %	11	68.7 %
I have some problems washing or dressing myself	3	33.3 %	.	.	1	25.0 %	.	.	4	25.0 %
I am unable to wash or dress myself
Unknown	1	25.0 %	.	.	1	6.2 %
TOTAL	9	100.0 %	1	100.0 %	4	100.0 %	2	100.0 %	16	100.0 %

EQ-5D Self Care	STS InterMACS											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
I have no problems with self-care	220	60.6 %	139	59.9 %	194	60.4 %	186	68.3 %	82	59.8 %	821	61.9 %
I have some problems washing or dressing myself	113	31.1 %	69	29.7 %	90	28.0 %	62	22.7 %	36	26.2 %	370	27.9 %
I am unable to wash or dress myself	22	6.0 %	17	7.3 %	23	7.1 %	19	6.9 %	10	7.2 %	91	6.8 %
Unknown	8	2.2 %	7	3.0 %	14	4.3 %	5	1.8 %	9	6.5 %	43	3.2 %
TOTAL	363	100.0 %	232	100.0 %	321	100.0 %	272	100.0 %	137	100.0 %	1325	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18c. Quality of Life - EQ-5D Usual Activities

The following table compares the EQ-5D Usual Activities domain between your site and STS InterMACS.

EQ-5D Usual Activities	HOSPX-9999									
	2020 Q1		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%
I have no problems with performing my usual activities	3	33.3 %	3	18.7 %
I have some problems with performing my usual activities	3	33.3 %	1	100.0 %	3	75.0 %	2	100.0 %	9	56.2 %
I am unable to perform my usual activities	3	33.3 %	3	18.7 %
Unknown	1	25.0 %	.	.	1	6.2 %
TOTAL	9	100.0 %	1	100.0 %	4	100.0 %	2	100.0 %	16	100.0 %

EQ-5D Usual Activities	STS InterMACS											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
I have no problems with performing my usual activities	88	24.2 %	58	25.0 %	80	24.9 %	75	27.5 %	34	24.8 %	335	25.2 %
I have some problems with performing my usual activities	185	50.9 %	110	47.4 %	149	46.4 %	134	49.2 %	64	46.7 %	642	48.4 %
I am unable to perform my usual activities	81	22.3 %	58	25.0 %	73	22.7 %	59	21.6 %	29	21.1 %	300	22.6 %
Unknown	9	2.4 %	6	2.5 %	19	5.9 %	4	1.4 %	10	7.2 %	48	3.6 %
TOTAL	363	100.0 %	232	100.0 %	321	100.0 %	272	100.0 %	137	100.0 %	1325	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18d. Quality of Life - EQ-5D Pain/Discomfort

The following table compares the EQ-5D Pain/Discomfort domain between your site and STS Intermacs.

EQ-5D Pain/Discomfort	HOSPX-9999									
	2020 Q1		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%
I have no pain or discomfort	6	66.6 %	6	37.5 %
I have moderate pain or discomfort	3	33.3 %	1	100.0 %	2	50.0 %	1	50.0 %	7	43.7 %
I have extreme pain or discomfort	1	25.0 %	1	50.0 %	2	12.5 %
Unknown	1	25.0 %	.	.	1	6.2 %
TOTAL	9	100.0 %	1	100.0 %	4	100.0 %	2	100.0 %	16	100.0 %

EQ-5D Pain/Discomfort	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
I have no pain or discomfort	171	47.1 %	92	39.6 %	139	43.3 %	141	51.8 %	58	42.3 %	601	45.3 %
I have moderate pain or discomfort	164	45.1 %	119	51.2 %	134	41.7 %	114	41.9 %	58	42.3 %	589	44.4 %
I have extreme pain or discomfort	16	4.4 %	13	5.6 %	30	9.3 %	12	4.4 %	9	6.5 %	80	6.0 %
Unknown	12	3.3 %	8	3.4 %	18	5.6 %	5	1.8 %	12	8.7 %	55	4.1 %
TOTAL	363	100.0 %	232	100.0 %	321	100.0 %	272	100.0 %	137	100.0 %	1325	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18e. Quality of Life - EQ-5D Anxiety/Depression

The following table compares the EQ-5D Anxiety/Depression domain between your site and STS InterMACS.

EQ-5D Anxiety	HOSPX-9999									
	2020 Q1		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%
I am not anxious or depressed	5	55.5 %	1	100.0 %	1	25.0 %	.	.	7	43.7 %
I am moderately anxious or depressed	2	22.2 %	.	.	2	50.0 %	2	100.0 %	6	37.5 %
I am extremely anxious or depressed	2	22.2 %	2	12.5 %
Unknown	1	25.0 %	.	.	1	6.2 %
TOTAL	9	100.0 %	1	100.0 %	4	100.0 %	2	100.0 %	16	100.0 %

EQ-5D Anxiety	STS InterMACS											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
I am not anxious or depressed	180	49.5 %	105	45.2 %	142	44.2 %	137	50.3 %	57	41.6 %	621	46.8 %
I am moderately anxious or depressed	155	42.6 %	109	46.9 %	137	42.6 %	112	41.1 %	59	43.0 %	572	43.1 %
I am extremely anxious or depressed	17	4.6 %	10	4.3 %	25	7.7 %	20	7.3 %	10	7.2 %	82	6.1 %
Unknown	11	3.0 %	8	3.4 %	17	5.2 %	3	1.1 %	11	8.0 %	50	3.7 %
TOTAL	363	100.0 %	232	100.0 %	321	100.0 %	272	100.0 %	137	100.0 %	1325	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 18f. Quality of Life - EQ-5D Visual Analog Scale

The following table compares the EQ-5D Visual Analog Scale domain between your site and STS Intermacs.

GROUP=HOSPX-9999

EQ-5D - VAS Score		2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	TOTAL
	N	9	0	1	4	1	0	15
	Mean	37.44	.	70.00	35.00	40.00	.	39.13
	Std	29.16	.	.	23.80	.	.	26.11
	Min	0.00	.	70.00	10.00	40.00	.	0.00
	Max	90.00	.	70.00	60.00	40.00	.	90.00

GROUP=STS Intermacs

[illegible]

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18g. Quality of Life - EQ-5D Incomplete - Patient Reasons**

The following table compares the Patient Reasons the EQ-5D was not completed.

Patient Reasons for Incomplete EQ-5D	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Too sick (ex., intubated/sedated, critically ill, on short-term VAD)	3	21.4 %	1	11.1 %	.	.	3	60.0 %	.	.	7	18.9 %
Too tired	2	14.2 %	1	20.0 %	.	.	3	8.1 %
Too stressed, anxious, and/or depressed
No time / too busy	3	21.4 %	1	11.1 %	2	25.0 %	6	16.2 %
Too much trouble / don't want to be bothered / not interested	1	7.1 %	1	11.1 %	1	12.5 %	3	8.1 %
Can't concentrate
Unwilling to complete instrument, no reason given	.	.	1	11.1 %	1	2.7 %
Unable to read English and/or illiterate	1	12.5 %	1	2.7 %
Administrative (check specific reason below)	5	35.7 %	5	55.5 %	4	50.0 %	1	20.0 %	1	100.0 %	16	43.2 %
TOTAL	14	100.0 %	9	100.0 %	8	100.0 %	5	100.0 %	1	100.0 %	37	100.0 %

Patient Reasons for Incomplete EQ-5D	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Too sick (ex., intubated/sedated, critically ill, on short-term VAD)	122	35.0 %	85	33.3 %	89	30.1 %	65	32.6 %	31	32.6 %	392	32.8 %
Too tired	5	1.4 %	2	0.7 %	6	2.0 %	5	2.5 %	2	2.1 %	20	1.6 %
Too stressed, anxious, and/or depressed	8	2.2 %	17	6.6 %	14	4.7 %	10	5.0 %	3	3.1 %	52	4.3 %
No time / too busy	33	9.4 %	20	7.8 %	28	9.4 %	20	10.0 %	10	10.5 %	111	9.3 %
Too much trouble / don't want to be bothered / not interested	5	1.4 %	5	1.9 %	9	3.0 %	3	1.5 %	2	2.1 %	24	2.0 %
Can't concentrate	4	1.1 %	1	0.3 %	.	.	2	1.0 %	.	.	7	0.5 %
Unwilling to complete instrument, no reason given	4	1.1 %	3	1.1 %	5	1.6 %	9	4.5 %	5	5.2 %	26	2.1 %
Unable to read English and/or illiterate	2	0.5 %	1	0.3 %	4	1.3 %	4	2.0 %	1	1.0 %	12	1.0 %
Administrative (check specific reason below)	165	47.4 %	121	47.4 %	140	47.4 %	81	40.7 %	41	43.1 %	548	45.9 %
TOTAL	348	100.0 %	255	100.0 %	295	100.0 %	199	100.0 %	95	100.0 %	1192	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT**II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life****Exhibit 18h. Quality of Life - EQ-5D Incomplete - Administrative Reasons**

The following table compares the Administrative Reasons the EQ-5D was not completed.

Administrative Reasons for Incomplete EQ-5D	HOSPX-9999											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Urgent/emergent implant, no time to administer QOL instruments	1	100.0 %	.	.	1	6.2 %
Coordinator too busy or forgot to administer QOL instruments	5	100.0 %	4	80.0 %	4	100.0 %	.	.	1	100.0 %	14	87.5 %
Unable to contact patient (ie., not hospitalized or no clinic visit) within the window for QOL instr	.	.	1	20.0 %	1	6.2 %
Other reason (describe)
TOTAL	5	100.0 %	5	100.0 %	4	100.0 %	1	100.0 %	1	100.0 %	16	100.0 %

Administrative Reasons for Incomplete EQ-5D	STS Intermacs											
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%
Urgent/emergent implant, no time to administer QOL instruments	10	6.0 %	7	5.7 %	1	0.7 %	4	4.9 %	1	2.4 %	23	4.1 %
Coordinator too busy or forgot to administer QOL instruments	85	51.5 %	39	32.2 %	52	37.1 %	36	44.4 %	19	46.3 %	231	42.1 %
Unable to contact patient (ie., not hospitalized or no clinic visit) within the window for QOL instr	8	4.8 %	21	17.3 %	27	19.2 %	11	13.5 %	8	19.5 %	75	13.6 %
Other reason (describe)	62	37.5 %	54	44.6 %	60	42.8 %	30	37.0 %	13	31.7 %	219	39.9 %
TOTAL	165	100.0 %	121	100.0 %	140	100.0 %	81	100.0 %	41	100.0 %	548	100.0 %

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.A. Pre-Implant Summaries - Functional Capacity and Quality of Life

Exhibit 19. Trailmaking

Trailmaking Test time is the number of seconds required to complete the test.

GROUP=HOSPX-9999

Trailmaking Time(s)	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	TOTAL
N	4	0	1	2	1	0	8
Mean	101.50	.	168.00	90.00	181.00	.	116.88
Std	57.98	.	.	7.07	.	.	52.44
Min	46.00	.	168.00	85.00	181.00	.	46.00
Max	183.00	.	168.00	95.00	181.00	.	183.00

GROUP=STS Intermacs

Trailmaking Time(s)	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	TOTAL
N	222	149	204	163	93	0	831
Mean	176.07	139.59	145.52	131.00	143.29	.	149.52
Std	337.30	73.08	99.61	96.29	75.13	.	190.76
Min	46.00	41.00	28.00	13.00	6.00	.	6.00
Max	3600.00	423.00	948.00	840.00	395.00	.	3600.00

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.B. Implant Summaries

Exhibit 20. VAD Indication

The following table summarizes additional implant reasons that necessitated the placement of a VAD at your site and STS InterMACS.

VAD INDICATION	HOSPX-9999		STS InterMACS	
	N	%	N	%
Failure to wean from Cardio Pulmonary Bypass	.	.	27	1.2 %
Persistent Heart Failure Following Cardiac Surgery	.	.	15	0.6 %
None	43	100.0 %	2123	98.0 %
Total Patients	43	100.0 %	2165	100.0 %

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.B. Implant Summaries

Exhibit 21. Device Type

The following tables summarize the implant side (location) of VADs at your site and STS InterMACs over time.

Device Type	HOSPX-9999													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
LVAD	22	95.6 %	9	90.0 %	9	100.0 %	9	81.8 %	13	100.0 %	9	100.0 %	71	94.6 %
RVAD
BIVAD	1	4.3 %	1	10.0 %	.	.	1	9.0 %	3	4.0 %
TAH	1	9.0 %	1	1.3 %
TOTAL	23	100.0 %	10	100.0 %	9	100.0 %	11	100.0 %	13	100.0 %	9	100.0 %	75	100.0 %

Device Type	STS InterMACs													
	2020 Q1		2020 Q2		2020 Q3		2020 Q4		2021 Q1		2021 Q2		TOTAL	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
LVAD	725	94.4 %	512	93.0 %	650	95.4 %	520	97.0 %	526	93.9 %	486	92.3 %	3419	94.4 %
RVAD	3	0.3 %	2	0.3 %	1	0.1 %	6	0.1 %
BIVAD	39	5.0 %	36	6.5 %	27	3.9 %	15	2.7 %	32	5.7 %	37	7.0 %	186	5.1 %
TAH	1	0.1 %	.	.	4	0.5 %	1	0.1 %	2	0.3 %	2	0.3 %	10	0.2 %
TOTAL	768	100.0 %	550	100.0 %	681	100.0 %	536	100.0 %	560	100.0 %	526	100.0 %	3621	100.0 %

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.B. Implant Summaries

Exhibit 22. Additional Interventions within 48 Hours of Implant

This table lists the interventions that occurred during the 48 hours prior to implant. A patient can have more than 1 additional intervention.

ADDITIONAL INTERVENTIONS	HOSPX-9999			STS InterMACS		
	N	Yes	%	N	Yes	%
IABP	43	2	4.65%	2168	230	10.61%
Dialysis	43	0	0.00%	2168	22	1.01%
Ultrafiltration	43	0	0.00%	2168	5	0.23%
Ventilator	43	0	0.00%	2168	42	1.94%
Feeding Tube	43	0	0.00%	2168	14	0.65%
ECMO	43	0	0.00%	2168	38	1.75%
None	43	41	95.35%	2168	1859	85.75%
CABG+	43	0	0.00%	2168	0	0.00%
Aortic Valve Replacement/Repair+	43	0	0.00%	2168	1	0.05%
Mitral Valve Replacement/Repair+	43	0	0.00%	2168	0	0.00%
Congenital Cardiac Surgery+	43	0	0.00%	2168	1	0.05%
LVAD+	43	0	0.00%	2168	0	0.00%
RVAD+	43	0	0.00%	2168	0	0.00%
TAH+	43	0	0.00%	2168	0	0.00%
Aneurysmectomy+	43	0	0.00%	2168	0	0.00%

Note: + = variable collected post relaunch (5/2/2012)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23a. Patient Percent Experiencing Each Adverse Event Type

For each adverse event type, the percent of patients with a least one event of that type reported is presented at for your site and STS-INTERMACS overall.

Patient percent experiencing a specific adverse event = number of unique patients with reported event / number of patients at your site * 100

While useful, this measure does not take into consideration the varying amount of time on support for each patient (exposure time) or the timing of the adverse events. Subsequent exhibits use adverse event rates that more accurately compare adverse events reported at your site to the overall cohort.

	HOSPX-9999			STS InterMACS		
	Events	Patients	Patient Percent	Events	Patients	Patient Percent
Arterial Non-CNS Thromboembolism	.	.	.	22	18	0.5%
Bleeding	14	10	13.3%	1155	754	20.8%
Cardiac Arrhythmia	9	9	12.0%	922	671	18.5%
Device Malfunction and/or Pump Thrombosis	4	4	5.3%	134	115	3.2%
Hepatic Dysfunction	.	.	.	90	87	2.4%
Infection	23	18	24.0%	1628	1032	28.5%
Myocardial Infarction	.	.	.	6	6	0.2%
Neurological Dysfunction	12	11	14.7%	501	413	11.4%
Other Serious Adverse Event	1	1	1.3%	1033	628	17.3%
Pericardial Drainage	.	.	.	75	70	1.9%
Psychiatric Episode	.	.	.	146	128	3.5%
Rehospitalization	62	28	37.3%	3716	1632	45.1%
Renal Dysfunction	4	4	5.3%	442	401	11.1%
Respiratory Failure	8	8	10.7%	622	502	13.9%
Venous Thromboembolism	3	3	4.0%	60	56	1.5%
Wound Dehiscence	1	1	1.3%	29	28	0.8%

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23b. Adverse Event Exposure

The following table summarizes the total time patients receiving primary prospective implants have been followed at your site and STS InterMACS overall. The total follow-up time is divided into an early period (less than or equal to three months) and late period (more than three months). These totals are the accrued exposure time for each patient group and are used as the denominators in the following rate calculations.

Patient Follow-Up	HOSPX-9999	STS InterMACS
Patient exposure during the first 3 months post implant (months)	170	9385
Patient exposure after the first 3 months post implant (months)	354	19510
Number of Patients	75	3621

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23c. Adverse Event Rates

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Bleeding	9	10.7%	5.28	5	5.3%	1.41
Cardiac Arrhythmia	8	10.7%	4.69	1	1.3%	0.28
Device Malfunction and/or Pump Thrombosis	4	5.3%	2.35	.	.	.
Infection	17	17.3%	9.98	6	8.0%	1.69
Neurological Dysfunction	10	13.3%	5.87	2	2.7%	0.56
Other Serious Adverse Event	1	1.3%	0.59	.	.	.
Rehospitalization	21	25.3%	12.32	41	24.0%	11.58
Renal Dysfunction	4	5.3%	2.35	.	.	.
Respiratory Failure	6	8.0%	3.52	2	2.7%	0.56
Venous Thromboembolism	3	4.0%	1.76	.	.	.
Wound Dehiscence	1	1.3%	0.59	.	.	.

GROUP=STS Intermacs

	STS Intermacs					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Arterial Non-CNS Thromboembolism	19	0.4%	0.20	3	0.1%	0.02
Bleeding	772	15.8%	8.23	383	7.7%	1.96
Cardiac Arrhythmia	738	16.0%	7.86	184	3.8%	0.94
Device Malfunction and/or Pump Thrombosis	72	1.9%	0.77	62	1.4%	0.32
Hepatic Dysfunction	64	1.7%	0.68	26	0.7%	0.13
Infection	949	19.3%	10.11	679	13.3%	3.48
Myocardial Infarction	4	0.1%	0.04	2	0.1%	0.01
Neurological Dysfunction	341	8.4%	3.63	160	3.6%	0.82
Other Serious Adverse Event	779	14.6%	8.30	254	5.1%	1.30
Pericardial Drainage	74	1.9%	0.79	1	0.0%	0.01
Psychiatric Episode	107	2.8%	1.14	39	0.9%	0.20
Rehospitalization	1406	28.3%	14.98	2310	30.7%	11.84
Renal Dysfunction	390	10.0%	4.16	52	1.3%	0.27
Respiratory Failure	558	13.0%	5.95	64	1.5%	0.33
Venous Thromboembolism	54	1.4%	0.58	6	0.2%	0.03
Wound Dehiscence	27	0.7%	0.29	2	0.1%	0.01

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23d. Infection Rates by Location

The following table compares infection rates according to location at your site and STS InterMACS. Every infection location reported is counted in the table.

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
GI	.	.	.	1	1.3%	0.28
Line Sepsis	3	4.0%	1.76	.	.	.
Mediastinum	1	1.3%	0.59	.	.	.
Other Specify	3	4.0%	1.76	.	.	.
Positive Blood Cultures	4	4.0%	2.35	1	1.3%	0.28
Pulmonary	8	10.7%	4.69	1	1.3%	0.28
Pump/Related - Drive Line	3	4.0%	1.76	1	1.3%	0.28
Unknown	.	.	.	1	1.3%	0.28
Urinary Tract	.	.	.	2	2.7%	0.56

GROUP=STS InterMACS

	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
GI	59	1.6%	0.63	20	0.6%	0.10
Line Sepsis	16	0.4%	0.17	16	0.4%	0.08
Mediastinum	34	0.9%	0.36	10	0.2%	0.05
Other Specify	152	3.8%	1.62	102	2.6%	0.52
Peripheral Wound	34	0.9%	0.36	23	0.5%	0.12
Positive Blood Cultures	220	5.5%	2.34	186	4.2%	0.95
Pulmonary	324	7.7%	3.45	93	2.4%	0.48
Pump/Related - Drive Line	90	2.4%	0.96	239	5.2%	1.22
Pump/Related - Exit Cannula	4	0.1%	0.04	9	0.2%	0.05
Pump/Related - Pump Interior	3	0.1%	0.03	3	0.1%	0.02
Pump/Related - Pump Pocket	6	0.2%	0.06	7	0.2%	0.04
Unknown	26	0.7%	0.28	17	0.4%	0.09
Urinary Tract	136	3.2%	1.45	77	1.8%	0.39

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23e. Bleeding Rates by Source

The following table compares bleeding rates according to source at your site and STS InterMACS. Every bleed source reported is counted in the table.

NOTE: These rates are reported for patients receiving a implant starting in March 2009.

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
ENT / Dental	2	2.7%	1.17	.	.	.
GI OVERALL: upper, lower, unknown	6	6.7%	3.52	3	4.0%	0.85
GI: Lower gastrointestinal (colon, rectum, and anus)	2	2.7%	1.17	.	.	.
GI: Upper gastrointestinal (esophagus, stomach, duod)	1	1.3%	0.59	1	1.3%	0.28
GI: unknown, but guaiac positive stools	3	4.0%	1.76	2	2.7%	0.56
Mediastinal: Unspecified	1	1.3%	0.59	.	.	.
Other	3	4.0%	1.76	.	.	.
Pulmonary	.	.	.	2	1.3%	0.56

GROUP=STS InterMACS

	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Device anastomosis	3	0.1%	0.03	.	.	.
ENT / Dental	49	1.2%	0.52	14	0.4%	0.07
GI OVERALL: upper, lower, unknown	358	8.0%	3.81	286	5.8%	1.47
GI: Lower gastrointestinal (colon, rectum, and anus)	99	2.4%	1.05	65	1.6%	0.33
GI: Upper gastrointestinal (esophagus, stomach, duod)	191	4.6%	2.04	158	3.5%	0.81
GI: unknown, but guaiac positive stools	82	2.0%	0.87	69	1.6%	0.35
Intra-abdominal	9	0.2%	0.10	5	0.1%	0.03
Mediastinal: Unspecified	47	1.2%	0.50	1	0.0%	0.01
Mediastinal: aortic-venous cannulation site	1	0.0%	0.01	.	.	.
Mediastinal: chest wall	58	1.5%	0.62	1	0.0%	0.01
Mediastinal: coagulopathy with no surgical site	14	0.4%	0.15	.	.	.
Mediastinal: inflow conduit	3	0.1%	0.03	.	.	.
Mediastinal: other surgical site	23	0.6%	0.25	.	.	.
Mediastinal: outflow conduit	6	0.2%	0.06	.	.	.
Mediastinal: outflow-aorta anastomosis	9	0.2%	0.10	1	0.0%	0.01
Other	197	4.3%	2.10	74	1.8%	0.38
Pleural space	45	1.2%	0.48	.	.	.
Pulmonary	22	0.6%	0.23	3	0.1%	0.02
Pump Pocket	.	.	.	1	0.0%	0.01
Retroperitoneal	9	0.2%	0.10	4	0.1%	0.02
Urinary tract	5	0.1%	0.05	10	0.2%	0.05

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23f. Device Malfunction and/or Pump Thrombosis by type

The following table compares Device Malfunction and/or Pump Thrombosis rates according to type at your site and STS InterMACS.

NOTE: These rates are reported for patients receiving implant starting with Version 4.0 (June 2, 2014).

GROUP=HOSPX-9999

	HOSPX-9999		
	Early (During the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)
Pump Thrombosis	3	4.0%	1.76

GROUP=STS InterMACS

	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
Device Malfunction	34	0.9%	0.36	26	0.6%	0.13
Pump Thrombosis	31	0.8%	0.33	23	0.6%	0.12

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Adverse Event Rates

Exhibit 23g. Neurological Dysfunction by Category

The following table compares neurological dysfunction rates according to category at your site and STS InterMACS.

NOTE: These rates are reported for patients receiving implant starting with Version 3.0 (May 2, 2012).

GROUP=HOSPX-9999

	HOSPX-9999					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
CVA	10	13.3%	5.87	2	2.7%	0.56

GROUP=STS InterMACS


	STS InterMACS					
	Early (During the First Three Months)			Late (After the First Three Months)		
	Episodes	Patient %	Rate (per 100 pt month)	Episodes	Patient %	Rate (per 100 pt month)
CVA	200	5.1%	2.13	83	2.1%	0.43
Confusion	23	0.6%	0.25	15	0.4%	0.08
Encephalopathy	75	1.9%	0.80	29	0.7%	0.15
Seizure	21	0.6%	0.22	11	0.3%	0.06
TIA	22	0.6%	0.23	22	0.6%	0.11

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 24a. Time to First Device Malfunction / Thrombus




Months after Device Implant	STS Intermacs	HOSPX-9999
1	98.7% (98.5%-98.9%)	95.7% (92.5%-97.6%)
3	97.9% (97.7%-98.2%)	94.0% (90.3%-96.4%)
6	97.3% (97.0%-97.6%)	94.0% (90.3%-96.4%)
9	96.6% (96.3%-97.0%)	94.0% (90.3%-96.4%)
12	95.4% (95.0%-95.9%)	94.0% (90.3%-96.4%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 24b. Time to First Infection




Months after Device Implant	STS Intermacs	HOSPX-9999
1	87.1% (86.6%-87.7%)	85.0% (80.0%-88.9%)
3	79.0% (78.3%-79.7%)	79.7% (74.1%-84.3%)
6	72.4% (71.5%-73.2%)	71.0% (64.4%-76.6%)
9	68.5% (67.6%-69.4%)	71.0% (64.4%-76.6%)
12	64.2% (63.1%-65.1%)	67.1% (59.6%-73.5%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 24c. Time to First Neurological Dysfunction



Months after Device Implant	STS Intermacs	HOSPX-9999
1	93.1% (92.6%-93.5%)	86.0% (81.3%-89.6%)
3	91.2% (90.7%-91.7%)	86.0% (81.3%-89.6%)
6	89.4% (88.8%-89.9%)	86.0% (81.3%-89.6%)
9	87.5% (86.9%-88.1%)	83.2% (77.6%-87.4%)
12	86.2% (85.5%-86.8%)	83.2% (77.6%-87.4%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 25. Hospital Days for Discharged Patients

This table compares hospital days (initial hospitalization) from implant date to discharge date for patients with submitted discharge forms. For most patients this is the date they were discharged alive on a device but for patients that died or were transplanted in the implantation hospitalization it is the death date or transplant date, respectively. The first section (All) compares overall hospital days. The remaining sections compare hospital days by each device type, LVAD, Bi-VAD and TAH respectively.

HOSPITAL DAYS FOR DISCHARGED PATIENTS			HOSPX-9999					
			2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2
All		N	16	9	7	7	9	2
		Mean	20.13	20.89	45.00	25.14	22.00	20.00
		Std	9.63	6.43	36.06	8.32	7.33	2.83
		Median	20	21	24	28	19	20
		Min	8	11	13	12	14	18
		Max	48	29	100	37	36	22
BiVAD		N	.	.	.	1	.	.
		Mean	.	.	.	29.00	.	.
		Std
		Median	.	.	.	29	.	.
		Min	.	.	.	29	.	.
		Max	.	.	.	29	.	.
LVAD		N	16	9	7	6	9	2
		Mean	20.13	20.89	45.00	24.50	22.00	20.00
		Std	9.63	6.43	36.06	8.92	7.33	2.83
		Median	20	21	24	25	19	20
		Min	8	11	13	12	14	18
		Max	48	29	100	37	36	22
RVAD		N
		Mean
		Std
		Median
		Min
		Max
TAH		N
		Mean
		Std
		Median
		Min
		Max

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 25. Hospital Days for Discharged Patients

HOSPITAL DAYS FOR DISCHARGED PATIENTS			STS InterMACS					
			2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2
All		N	672	495	598	478	494	343
		Mean	27.24	25.19	26.88	25.53	24.99	21.23
		Std	28.10	17.88	21.98	18.35	16.46	11.37
		Median	20	20	20	20	20	18
		Min	0	3	1	5	5	0
		Max	387	140	164	177	120	81
BiVAD		N	25	25	18	9	21	13
		Mean	46.80	40.36	46.28	39.33	29.71	34.38
		Std	37.09	25.73	17.52	15.53	9.23	16.89
		Median	32	34	42	29	27	36
		Min	17	14	23	25	17	0
		Max	154	134	77	61	47	71
LVAD		N	646	469	578	469	471	330
		Mean	26.51	24.40	26.28	25.26	24.61	20.71
		Std	27.46	17.05	21.88	18.32	16.47	10.81
		Median	20	20	19	20	20	18
		Min	0	3	1	5	5	0
		Max	387	140	164	177	120	81
RVAD		N	1	1
		Mean	7.00	17.00
		Std
		Median	7	17
		Min	7	17
		Max	7	17
TAH		N	.	.	2	.	2	.
		Mean	.	.	28.00	.	65.00	.
		Std	.	.	7.07	.	25.46	.
		Median	.	.	28	.	65	.
		Min	.	.	23	.	47	.
		Max	.	.	33	.	83	.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - 30 Day Readmission

Exhibit 26. 30 Days Readmission

The following tables present the counts and percentages of patients that were discharged alive on a device that were readmitted within 30 days for your site and for STS InterMACS overall. Percentages are listed by device type and discharge year.

GROUP=HOSPX-9999

30 Day Readmission		Device Type						TOTAL		
		LVAD			BiVAD					
		Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission
Discharge Year										
	2020Q1	16	5	31.3%	.	.	.	16	5	31.3%
	2020Q2	5	2	40.0%	.	.	.	5	2	40.0%
	2020Q3	9	2	22.2%	.	.	.	9	2	22.2%
	2020Q4	7	2	28.6%	.	.	.	7	2	28.6%
	2021Q1	8	2	25.0%	1	0	0.0%	9	2	22.2%
	2021Q2	4	1	25.0%	.	.	.	4	1	25.0%
	TOTAL	49	14	28.6%	1	0	0.0%	50	14	28.0%

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - 30 Day Readmission

Exhibit 26. 30 Days Readmission

GROUP=STS Intermacs

30 Day Readmission		Device Type								
		LVAD			RVAD			BiVAD		
		Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission
Discharge Year										
	2020Q1	493	118	23.9%	.	.	.	11	3	27.3%
	2020Q2	454	113	24.9%	.	.	.	25	7	28.0%
	2020Q3	573	136	23.7%	1	0	0.0%	24	4	16.7%
	2020Q4	530	128	24.2%	.	.	.	10	4	40.0%
	2021Q1	422	112	26.5%	.	.	.	19	3	15.8%
	2021Q2	471	99	21.0%	.	.	.	21	6	28.6%
	TOTAL	2943	706	24.0%	1	0	0.0%	110	27	24.5%

30 Day Readmission		Device Type			TOTAL		
		TAH					
		Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission	Patients Discharged Alive on Device (n)	Patients with 30 day Readmission	% With 30 day Readmission
Discharge Year							
	2020Q1	.	.	.	504	121	24.0%
	2020Q2	.	.	.	479	120	25.1%
	2020Q3	2	2	100.0%	600	142	23.7%
	2020Q4	.	.	.	540	132	24.4%
	2021Q1	.	.	.	441	115	26.1%
	2021Q2	2	1	50.0%	494	106	21.5%
	TOTAL	4	3	75.0%	3058	736	24.1%

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27a. 6 Minute Walk - Overall

The following tables summarize Six Minute Walk completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	75	60	80.0	11	14.7	4	5.3	1122.5	238.1	1095.0	900.0	1400.0
3 Month	35	22	62.9	2	5.7	11	31.4	981.9	196.4	975.0	745.0	1375.0
6 Month	26	15	57.7	1	3.8	10	38.5	828.4	211.4	832.5	500.0	1200.0
1 Year	10	8	80.0	.	.	2	20.0	770.0	346.5	770.0	525.0	1015.0

GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS												
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
		N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3621	2018	55.7	1035	28.6	3	0.1	565	15.6	828.2	391.2	810.0	0.0	2300.0
3 Month	2447	1635	66.8	204	8.3	3	0.1	605	24.7	1043.8	358.1	1050.0	26.0	2320.0
6 Month	1836	1175	64.0	112	6.1	6	0.3	543	29.6	1058.8	376.3	1099.0	2.0	2175.0
1 Year	711	445	62.6	39	5.5	2	0.3	225	31.6	1038.1	405.4	1084.0	50.0	2145.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27a. 6 Minute Walk - Overall

The following figure summarize Six Minute Walk - Overall values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27b. 6 Minute Walk - LVAD

The following tables summarize Six Minute Walk completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	71	58	81.7	9	12.7	4	5.6	1122.5	238.1	1095.0	900.0	1400.0
3 Month	34	22	64.7	2	5.9	10	29.4	988.6	205.7	987.5	745.0	1375.0
6 Month	26	15	57.7	1	3.8	10	38.5	828.4	211.4	832.5	500.0	1200.0
1 Year	10	8	80.0	.	.	2	20.0	770.0	346.5	770.0	525.0	1015.0

GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS												
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
		N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3419	1918	56.1	946	27.7	3	0.1	552	16.1	829.5	394.4	810.0	0.0	2300.0
3 Month	2347	1581	67.4	181	7.7	3	0.1	582	24.8	1044.6	359.9	1050.0	26.0	2320.0
6 Month	1771	1136	64.1	103	5.8	6	0.3	526	29.7	1059.4	374.5	1099.5	2.0	2175.0
1 Year	683	428	62.7	36	5.3	2	0.3	217	31.8	1045.3	403.8	1092.0	100.0	2145.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27b. 6 Minute Walk - LVAD

The following figure summarize Six Minute Walk - LVAD values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27c. 6 Minute Walk - BiVAD

The following tables summarize Six Minute Walk completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3	2	66.7	1	33.3
3 Month	1	1	100.0	915.0	.	915.0	915.0	915.0

GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
	N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	186	92	49.5	82	44.1	12	6.5	757.8	217.2	802.5	425.0	1140.0
3 Month	93	51	54.8	22	23.7	20	21.5	1010.7	304.6	984.0	443.0	1500.0
6 Month	60	36	60.0	9	15.0	15	25.0	1017.1	460.7	1099.0	3.0	1698.0
1 Year	26	15	57.7	3	11.5	8	30.8	842.5	428.1	883.0	50.0	1478.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27c. 6 Minute Walk - BiVAD

The following figure summarize Six Minute Walk - BiVAD values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27d. 6 Minute Walk - TAH

The following tables summarize Six Minute Walk completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS		Six Minute Walk (ft)				
		Not Done: Too Sick						
	N	N	%	Mean	Std	Median	Min	Max
Pre-Implant	1	1	100.0

GROUP=STS InterMACS

VISIT		COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
	Patients (n)							Six Minute Walk (ft)				
	N	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	10	5	50.0	4	40.0	1	10.0	950.0	.	950.0	950.0	950.0
3 Month	4	1	25.0	1	25.0	2	50.0	970.0	537.4	970.0	590.0	1350.0
6 Month	2	2	100.0	1225.0	247.5	1225.0	1050.0	1400.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 27d. 6 Minute Walk - TAH

The following figure summarize Six Minute Walk - TAH values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 28. VO2 Max

The following tables summarize VO2 Max completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT		COMPLETION STATUS				VO2 Max (mL/kg/min)				
		Not Done: Other/Unknown		Not Done: Too Sick						
	Patients (n)	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	75	63	84.0	12	16.0
3 Month	35	34	97.1	1	2.9
6 Month	26	26	100.0
1 Year	10	10	100.0

GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS												
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
		N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3621	2549	70.4	840	23.2	3	0.1	229	6.3	11.3	6.3	10.5	0.9	63.0
3 Month	2447	2321	94.9	124	5.1	2	0.1
6 Month	1836	1756	95.6	72	3.9	.	.	8	0.4	20.0	17.7	15.2	9.4	63.0
1 Year	711	689	96.9	21	3.0	.	.	1	0.1	11.0	.	11.0	11.0	11.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 28. VO2 Max

The following figure summarize VO2 Max values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 29. Peak R

The following tables summarize Peak R completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS		Peak R (%)				
		Not Done: Other/Unknown						
	N	N	%	Mean	Std	Median	Min	Max
Pre-Implant	75	75	100.0
3 Month	35	35	100.0
6 Month	26	26	100.0
1 Year	10	10	100.0

GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS						Peak R (%)					
		Not Done: Other/Unknown		Outlier		Complete							
	N	N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	3621	3448	95.2	37	1.0	136	3.8	1.1	0.2	1.1	0.7	1.7	
3 Month	2447	2447	100.0	
6 Month	1836	1831	99.7	.	.	5	0.3	1.3	0.1	1.3	1.1	1.4	
1 Year	711	710	99.9	.	.	1	0.1	1.2	.	1.2	1.2	1.2	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 29. Peak R

The following figure summarize Peak R values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 30. Gait Speed

The following tables summarize Gait Speed completion status and values at your site and STS InterMACs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS						Gait Speed (Feet/Sec) - DV				
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
	N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	75	63	84.0	12	16.0
3 Month	35	23	65.7	2	5.7	10	28.6	3.0	0.5	3.0	2.1	3.8
6 Month	26	17	65.4	1	3.8	8	30.8	2.6	0.5	2.5	1.9	3.8
1 Year	10	8	80.0	.	.	2	20.0	2.0	0.7	2.0	1.5	2.5

GROUP=STS InterMACs

VISIT	Patients (n)	COMPLETION STATUS								Gait Speed (Feet/Sec) - DV				
		Not Done: Other/Unknown		Not Done: Too Sick		Outlier		Complete						
	N	%	N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	3621	2501	69.1	976	27.0	15	0.4	129	3.6	2.9	1.8	2.7	0.0	10.0
3 Month	2447	1953	79.8	180	7.4	2	0.1	312	12.8	3.2	1.3	3.0	0.0	10.0
6 Month	1836	1456	79.3	106	5.8	1	0.1	273	14.9	3.6	1.5	3.4	0.0	10.0
1 Year	711	560	78.8	35	4.9	1	0.1	115	16.2	3.4	1.3	3.2	0.1	10.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 30. Gait Speed

The following figure summarize Gait Speed values your site and STS InterMACs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 31. Trailmaking

The following tables summarize Trailmaking completion status and values at your site and STS Intermacs at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS				Trailmaking Time (sec)				
		Incomplete		Complete						
	N	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	75	67	89.3	8	10.7	116.9	52.4	93.5	46.0	183.0
3 Month	35	28	80.0	7	20.0	112.6	46.7	108.0	52.0	199.0
6 Month	26	24	92.3	2	7.7	53.5	30.4	53.5	32.0	75.0
1 Year	10	8	80.0	2	20.0	154.0	11.3	154.0	146.0	162.0

GROUP=STS Intermacs

VISIT	Patients (n)	COMPLETION STATUS				Trailmaking Time (sec)				
		Incomplete		Complete						
	N	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3621	2790	77.1	831	22.9	149.5	190.8	120.0	6.0	3600.0
3 Month	2447	1829	74.7	618	25.3	119.5	90.2	97.0	9.0	1423.0
6 Month	1836	1314	71.6	522	28.4	106.2	57.5	95.0	9.0	561.0
1 Year	711	471	66.2	240	33.8	122.2	143.8	96.5	8.0	2134.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 31. Trailmaking

The following figure summarize Trailmaking values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 32. NYHA Class

The following tables summarize NYHA completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS				NYHA Class				
		Not Done: Other/Unknown		Complete						
	N	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	75	22	29.3	53	70.7	4.0	0.2	4.0	3.0	4.0
3 Month	35	7	20.0	28	80.0	2.7	1.0	2.0	1.0	4.0
6 Month	26	4	15.4	22	84.6	2.4	0.9	2.0	1.0	4.0
1 Year	10	.	.	10	100.0	2.0	0.5	2.0	1.0	3.0

GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS				NYHA Class				
		Not Done: Other/Unknown		Complete						
	N	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3621	919	25.4	2702	74.6	3.8	0.4	4.0	1.0	4.0
3 Month	2447	325	13.3	2122	86.7	2.4	0.8	2.0	1.0	4.0
6 Month	1836	197	10.7	1639	89.3	2.3	0.8	2.0	1.0	4.0
1 Year	711	74	10.4	637	89.6	2.2	0.8	2.0	1.0	4.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Functional Capacity

Exhibit 32. NYHA Class

The following figure summarize NYHA Class values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Quality of Life

Exhibit 33a. EQ-5D Index

The following tables summarize EQ-5D Index completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS						EQ-5D Index					
		Not Done: Other/Unknown		Not Done: Too Sick		Complete							
	N	%	N	%	N	%	Mean	Std	Median	Min	Max		
Pre-Implant	75	53	70.7	7	9.3	15	20.0	0.7	0.2	0.7	0.2	1.0	
3 Month	35	15	42.9	1	2.9	19	54.3	0.7	0.2	0.7	0.3	1.0	
6 Month	26	10	38.5	1	3.8	15	57.7	0.7	0.2	0.8	0.1	1.0	
1 Year	10	5	50.0	.	.	5	50.0	0.9	0.1	0.8	0.8	1.0	

GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS											
		Not Done: Other/Unknown		Not Done: Too Sick		Complete							
		N	%	N	%	N	%	Mean	Std	Median	Min	Max	
Pre-Implant	3621	1985	54.8	392	10.8	1244	34.4	0.7	0.2	0.8	-0.1	1.0	
3 Month	2447	1399	57.2	68	2.8	980	40.0	0.8	0.2	0.8	-0.1	1.0	
6 Month	1836	954	52.0	30	1.6	852	46.4	0.8	0.2	0.8	-0.1	1.0	
1 Year	711	343	48.2	6	0.8	362	50.9	0.8	0.2	0.8	0.1	1.0	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Quality of Life

Exhibit 33a. EQ-5D Index

The following figure summarize EQ-5D Index values your site and STS Intermacs at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Quality of Life

Exhibit 33b. EQ-5D Visual Analog Scale

The following tables summarize EQ-5D Visual Analog Scale completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS						VAS: Own Health State				
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
	N	N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	75	53	70.7	7	9.3	15	20.0	39.1	26.1	37.0	0.0	90.0
3 Month	35	12	34.3	1	2.9	22	62.9	70.5	21.4	77.5	30.0	100.0
6 Month	26	11	42.3	1	3.8	14	53.8	71.8	14.9	75.0	45.0	95.0
1 Year	10	5	50.0	.	.	5	50.0	74.0	15.2	80.0	50.0	90.0

GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS						VAS: Own Health State				
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3621	2007	55.4	392	10.8	1222	33.7	51.2	23.9	50.0	0.0	100.0
3 Month	2447	1428	58.4	68	2.8	951	38.9	71.6	18.6	75.0	0.0	100.0
6 Month	1836	981	53.4	30	1.6	825	44.9	73.5	19.1	75.0	0.0	100.0
1 Year	711	354	49.8	6	0.8	351	49.4	72.4	19.3	75.0	0.0	100.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Quality of Life

Exhibit 33b. EQ-5D Visual Analog Scale

The following figure summarize EQ-5D Visual Analog Scale values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Quality of Life

Exhibit 33c. KCCQ-12 - Scored

The following tables summarize KCCQ-12 - Scored completion status and values at your site and STS InterMACS at select follow-up visits. Only follow-up data for patients first devices are considered for this summary. Unlikely values have been categorized as outliers and are listed in the accompanying data quality report.

GROUP=HOSPX-9999

VISIT	Patients (n)	COMPLETION STATUS										
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	75	53	70.7	7	9.3	15	20.0	32.2	16.1	33.3	6.8	62.5
3 Month	35	12	34.3	1	2.9	22	62.9	56.8	27.8	53.7	12.0	100.0
6 Month	26	11	42.3	1	3.8	14	53.8	59.0	24.6	61.0	17.7	90.6
1 Year	10	6	60.0	.	.	4	40.0	70.8	18.9	75.0	45.8	87.5

GROUP=STS InterMACS

VISIT	Patients (n)	COMPLETION STATUS						KCCQ-12 Score				
		Not Done: Other/Unknown		Not Done: Too Sick		Complete						
		N	%	N	%	N	%	Mean	Std	Median	Min	Max
Pre-Implant	3621	1850	51.1	409	11.3	1362	37.6	36.5	21.2	33.9	0.0	100.0
3 Month	2447	1269	51.9	77	3.1	1101	45.0	60.9	21.3	62.5	0.0	100.0
6 Month	1836	840	45.8	33	1.8	963	52.5	64.0	20.8	66.1	0.0	100.0
1 Year	711	313	44.0	6	0.8	392	55.1	63.0	20.8	65.6	0.0	100.0

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients


COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

II.C. Post Implant Summary - Quality of Life

Exhibit 33c. KCCQ-12 - Scored

The following figure summarize KCCQ-12 - Scored values your site and STS InterMACS at select follow-up visits. Only follow-up data for patients' first devices are considered for this summary. The dots represent average values and the error bars are the standard errors.



STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients***COVERAGE: January 1, 2020 - June 30, 2021******SITE: HOSPX - DEMO SITE REPORT******II.E. Post Implant Outcomes***

This section provides statistical summaries of outcomes after VAD implant. These depictions include all patients who received a primary device at your institution and compares it with the equivalent group in InterMACS. The p-values are a univariate comparison (log-rank test) of survival at your institution with survival for the entire registry. Univariate comparisons are well known to be limited in value because no adjustment is made for differing patient characteristics in the groups. Nevertheless, these comparisons can provide an initial comparison of unadjusted results. Future version of this report will provide risk adjusted comparisons.

Note: If your site did not report any patients within a specified group, only the overall STS InterMACS data will be displayed.


STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 34a. Post Implant Survival - Device Sequence - STS InterMACs

The following figure compares survival time on specific devices based on device sequence for all of STS InterMACs. Each curve represents survival from the time the device was implanted until death. Patients are censored at time of transplant, explant for any reason, or the device was turned off.



Months after Device Implant	1st Device	2nd Device	3rd Device
1	94.4% (94.0%-94.8%)	64.6% (59.6%-69.1%)	75.0% (55.7%-86.8%)
3	90.8% (90.3%-91.3%)	57.9% (52.6%-62.8%)	
6	88.4% (87.8%-89.0%)	48.7% (42.8%-54.3%)	
9	86.8% (86.2%-87.5%)	39.3% (33.0%-45.6%)	
12	84.7% (84.0%-85.4%)	39.3% (33.0%-45.6%)	


STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 34b. Post Implant Survival - Device Sequence - HOSPX-9999

The following figure compares survival time on specific devices based on device sequence for your site. Each curve represents survival from the time the device was implanted until death. Patients are censored at transplant, explant for any reason, or the device was turned off.




Months after Device Implant	1st Device	2nd Device
1	86.0% (81.3%-89.6%)	50.0% (14.6%-77.9%)
3	74.1% (68.4%-79.0%)	
6	74.1% (68.4%-79.0%)	
9	69.3% (63.0%-74.8%)	
12	69.3% (63.0%-74.8%)	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 35. Post Implant Survival - PRIMARY OVERALL




Months after Device Implant	STS InterMACS	HOSPX-9999
1	93.6% (93.1%-94.0%)	84.7% (79.9%-88.5%)
3	89.7% (89.1%-90.2%)	73.0% (67.3%-77.9%)
6	87.1% (86.6%-87.7%)	73.0% (67.3%-77.9%)
9	85.4% (84.7%-86.0%)	68.3% (62.0%-73.8%)
12	83.3% (82.6%-84.0%)	68.3% (62.0%-73.8%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 36. Post Implant Survival - Primary LVADs




Months after Device Implant	STS InterMACS	HOSPX-9999
1	94.0% (93.6%-94.4%)	88.3% (83.7%-91.6%)
3	90.5% (90.0%-91.0%)	75.9% (70.1%-80.7%)
6	88.1% (87.5%-88.7%)	75.9% (70.1%-80.7%)
9	86.4% (85.7%-87.0%)	71.0% (64.5%-76.5%)
12	84.5% (83.8%-85.2%)	71.0% (64.5%-76.5%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 37a. Post Implant Survival - Primary LVADs by Era - STS InterMACS




Months after Device Implant	2020-2021
1	93.9% (93.4%-94.4%)
3	90.2% (89.6%-90.8%)
6	87.9% (87.3%-88.6%)
9	86.2% (85.5%-86.9%)
12	84.3% (83.5%-85.1%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 37b. Post Implant Survival - Primary LVADs by Era - HOSPX-9999




Months after Device Implant	2020-2021
1	85.7% (79.8%-90.0%)
3	71.4% (64.4%-77.3%)
6	71.4% (64.4%-77.3%)
9	66.8% (59.5%-73.1%)
12	66.8% (59.5%-73.1%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 38. Post Implant Survival - Primary BiVADs




Months after Device Implant	STS Intermacs	HOSPX-9999
1	86.3% (83.5%-88.6%)	33.3% (9.9%-59.3%)
3	74.9% (71.4%-78.1%)	33.3% (9.9%-59.3%)
6	70.5% (66.6%-74.0%)	33.3% (9.9%-59.3%)
9	67.0% (62.8%-70.8%)	
12	61.1% (56.3%-65.5%)	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 39. Post Implant Survival - Primary TAHs



Months after Device Implant	STS InterMACS	HOSPX-9999
1	78.8% (61.4%-88.9%)	0.0% (0.0%-0.0%)
3	78.8% (61.4%-88.9%)	
6	52.5% (27.8%-72.3%)	
9	52.5% (27.8%-72.3%)	
12	52.5% (27.8%-72.3%)	

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 40. Post Implant Survival - Primary LVADs - PULSATILE FLOW


Not enough patients or events to produce exhibit

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 41. Post Implant Survival - Primary LVADs - CONTINUOUS FLOW




Months after Device Implant	STS InterMACS	HOSPX-9999
1	94.0% (93.6%-94.4%)	88.3% (83.7%-91.6%)
3	90.5% (90.0%-91.0%)	75.9% (70.1%-80.7%)
6	88.1% (87.5%-88.7%)	75.9% (70.1%-80.7%)
9	86.4% (85.7%-87.0%)	71.0% (64.5%-76.5%)
12	84.5% (83.8%-85.2%)	71.0% (64.5%-76.5%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 42. Post Implant Survival - Listed for Transplant - CONTINUOUS FLOW




Months after Device Implant	STS Intermacs	HOSPX-9999
1	95.3% (93.7%-96.6%)	66.7% (33.0%-86.2%)
3	92.9% (90.8%-94.4%)	33.3% (9.9%-59.3%)
6	90.4% (88.0%-92.3%)	33.3% (9.9%-59.3%)
9	89.6% (87.1%-91.6%)	33.3% (9.9%-59.3%)
12	89.6% (87.1%-91.6%)	33.3% (9.9%-59.3%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 43. Post Implant Survival - Bridge to Candidacy - CONTINUOUS FLOW




Months after Device Implant	STS Intermacs	HOSPX-9999
1	95.0% (93.9%-95.8%)	90.9% (77.2%-96.6%)
3	90.6% (89.2%-91.9%)	81.8% (66.5%-90.6%)
6	88.7% (87.2%-90.1%)	81.8% (66.5%-90.6%)
9	87.4% (85.8%-88.9%)	81.8% (66.5%-90.6%)
12	86.2% (84.4%-87.8%)	81.8% (66.5%-90.6%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 44. Post Implant Survival - Destination Therapy - CONTINUOUS FLOW




Months after Device Implant	STS InterMACS	HOSPX-9999
1	93.2% (92.7%-93.7%)	85.7% (80.3%-89.7%)
3	89.1% (88.5%-89.7%)	74.3% (67.8%-79.7%)
6	86.6% (85.9%-87.2%)	74.3% (67.8%-79.7%)
9	84.7% (83.9%-85.4%)	67.9% (60.3%-74.3%)
12	82.2% (81.3%-83.1%)	67.9% (60.3%-74.3%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45a. Post Implant Survival: Patient Profile 1 - Critical Cardiogenic Shock




Months after Device Implant	STS Intermacs	HOSPX-9999
1	88.6% (87.1%-90.1%)	50.0% (14.6%-77.9%)
3	82.6% (80.7%-84.4%)	50.0% (14.6%-77.9%)
6	79.9% (77.9%-81.8%)	50.0% (14.6%-77.9%)
9	77.3% (75.1%-79.4%)	50.0% (14.6%-77.9%)
12	74.7% (72.3%-77.0%)	50.0% (14.6%-77.9%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45b. Post Implant Survival: Patient Profile 2 - Progressive Decline




Months after Device Implant	STS InterMACS	HOSPX-9999
1	93.3% (92.5%-94.0%)	80.0% (69.2%-87.4%)
3	89.4% (88.4%-90.3%)	70.0% (58.4%-78.9%)
6	86.6% (85.5%-87.6%)	70.0% (58.4%-78.9%)
9	84.8% (83.6%-85.9%)	63.0% (50.5%-73.1%)
12	82.8% (81.5%-84.1%)	63.0% (50.5%-73.1%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45c. Post Implant Survival: Patient Profile 3 - Stable but Inotrope Dependent



InterMACS


Months after Device Implant	STS InterMACS	HOSPX-9999
1	94.7% (94.1%-95.3%)	91.3% (86.1%-94.7%)
3	90.8% (90.0%-91.6%)	77.3% (70.2%-82.9%)
6	88.5% (87.6%-89.4%)	77.3% (70.2%-82.9%)
9	86.7% (85.7%-87.7%)	73.4% (65.6%-79.8%)
12	84.8% (83.7%-85.9%)	73.4% (65.6%-79.8%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 45d. Post Implant Survival: Patient Profile 4+ Resting Symptoms and Less Sick




Months after Device Implant	STS Intermacs	HOSPX-9999
1	95.2% (94.1%-96.0%)	50.0% (24.0%-71.4%)
3	93.1% (91.9%-94.2%)	50.0% (24.0%-71.4%)
6	90.8% (89.4%-92.1%)	50.0% (24.0%-71.4%)
9	90.2% (88.7%-91.5%)	50.0% (24.0%-71.4%)
12	88.0% (86.1%-89.6%)	50.0% (24.0%-71.4%)

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 46a. Competing Outcomes - Primary LVADs - CONTINUOUS FLOW - STS Intermacs




Outcome	Months After Device Implant				
	1	3	6	9	12
Alive (device still in place)	94.0%	89.9%	86.1%	82.3%	78.4%
Transplant	0.1%	0.6%	1.9%	4.0%	6.0%
Death (before transplant)	6.0%	9.5%	11.9%	13.5%	15.3%
Cessation of support	0.0%	0.1%	0.2%	0.2%	0.3%
Total	100%	100%	100%	100%	100%

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 46b. Competing Outcomes - Primary LVADs - CONTINUOUS FLOW - HOSPX-9999



Outcome	Months After Device Implant				
	1	3	6	9	12
Alive (device still in place)	88.3%	75.9%	74.1%	67.2%	64.4%
Transplant	0.0%	0.0%	1.8%	4.0%	6.8%
Death (before transplant)	11.7%	24.1%	24.1%	28.8%	28.8%
Total	100%	100%	100%	100%	100%

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 47a. Competing Outcomes - Primary TAHs - STS Intermacs

Not enough patients or events to produce exhibit

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 47b. Competing Outcomes - Primary TAHs - HOSPX-9999

Not enough patients or events to produce exhibit

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients***COVERAGE: January 1, 2020 - June 30, 2021******SITE: HOSPX - DEMO SITE REPORT******IV. Zone Conditions: Hemolysis, Hypertension, and Right Heart Failure***

The following Exhibits consist of data collected regarding the three “Zone Conditions”: Hemolysis, Hypertension, and Right Heart Failure. These zones were added to the STS InterMACS released in June of 2014. The zone sections, including data fields and flag calculations, were added to the Web Based Data Entry (WBDE) system. In the WBDE, the flags are calculated on any applicable form that is updated by a user after the release date, and the flags are displayed in the WBDE (on the Patient Summary). The report exhibits on the following pages provide useful, clinical analysis of the flags by adding comparison to the STS InterMACS Aggregate Group, and include some further division into relevant categories, such as classification of severity, and timing.

Note: Further information on the calculation and processing of the Zone Conditions can be found on the [InterMACS.org](https://www.stsintermacs.org) website, in the Reports FAQ section. For any queries about the zone conditions or the exhibits, please don't hesitate to contact the InterMACS Data Warehouse and Analytics Center.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 48a: Hemolysis Evaluation Condition Coverage at Follow-up

The table below consists of data that was collected in the Hemolysis Zone for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. In the 'Unable to Evaluate' column, the condition could not be evaluated due to missing variables.

GROUP=HOSPX-9999

Follow-up Visit	Hemolysis Evaluation		
	All	Condition Evaluated	
		N	%
3 Month	35	35	100.00
6 Month	26	26	100.00
1 Year	10	10	100.00

GROUP=STS Intermacs

Follow-up Visit	Hemolysis Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	2447	121	4.94	2326	95.06
6 Month	1836	93	5.07	1743	94.93
1 Year	711	27	3.80	684	96.20

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

IV. Zone Conditions: Hemolysis

Exhibit 48b: Hemolysis Major and Minor Condition Coverage at Follow-up

The table below consists of patients who had Major or Minor Hemolysis Conditions for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit.

GROUP=HOSPX-9999

Follow-up Visit	Hemolysis Condition						
	All	Major		Minor		No	
	N	N	%	N	%	N	%
3 Month	35	2	5.71	5	14.29	28	80.00
6 Month	26	1	3.85	1	3.85	24	92.31
1 Year	10	1	10.00	2	20.00	7	70.00

GROUP=STS Intermacs

Follow-up Visit	Hemolysis Condition						
	All	Major		Minor		No	
	N	N	%	N	%	N	%
3 Month	2326	48	2.06	317	13.63	1961	84.31
6 Month	1743	22	1.26	210	12.05	1511	86.69
1 Year	684	16	2.34	94	13.74	574	83.92

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 48c: Hypertension Evaluation Condition Coverage at Follow-up

The table below consists of data that was collected in the Hypertension Zone for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. In the 'Unable to Evaluate' column, the condition could not be evaluated due to missing variables.

GROUP=HOSPX-9999

Follow-up Visit	Hypertension Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	35	20	57.14	15	42.86
6 Month	26	14	53.85	12	46.15
1 Year	10	8	80.00	2	20.00

GROUP=STS Intermacs

Follow-up Visit	Hypertension Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	2447	581	23.74	1866	76.26
6 Month	1836	416	22.66	1420	77.34
1 Year	711	184	25.88	527	74.12

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 48d: Hypertension No or Yes Condition Coverage at Follow-up

The table below consists of patients who did or did not have Hypertension Conditions for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit.

GROUP=HOSPX-9999

Follow-up Visit	Hypertension Condition				
	All	HTN		No HTN	
	N	N	%	N	%
3 Month	15	.	.	15	100.00
6 Month	12	1	8.33	11	91.67
1 Year	2	1	50.00	1	50.00

GROUP=STS InterMACS

Follow-up Visit	Hypertension Condition				
	All	HTN		No HTN	
	N	N	%	N	%
3 Month	1866	75	4.02	1791	95.98
6 Month	1420	64	4.51	1356	95.49
1 Year	527	20	3.80	507	96.20

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

IV. Zone Conditions: Right Heart Failure

Exhibit 48e: Right Heart Failure Evaluation Condition Coverage at Follow-up

The table below consists of data that was collected in the Right Heart Failure Zone for each Follow-Up interval. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. In the 'Unable to Evaluate' column, the condition could not be evaluated due to missing variables.

GROUP=HOSPX-9999

Follow-up Visit	RHF Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	35	1	2.86	34	97.14
6 Month	26	.	.	26	100.00
1 Year	10	.	.	10	100.00

GROUP=STS Intermacs

Follow-up Visit	RHF Evaluation				
	All	Unable to Evaluate		Condition Evaluated	
		N	%	N	%
3 Month	2447	100	4.09	2347	95.91
6 Month	1836	65	3.54	1771	96.46
1 Year	711	28	3.94	683	96.06

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 48f: Right Heart Failure Evaluation Condition Coverage at Follow-up

The table below consists of patients who Right Heart Failure for each Follow-Up interval, including analysis of severity. Patients that were implanted with a Primary Device on or after June 2, 2014 are analyzed in this exhibit. For full details on how each severity level is calculated, please check the Reports FAQ section on the Intermacs.org website.

GROUP=HOSPX-9999

Follow-up Visit	RHF Condition						
	1. No RHF			3. RHF (Mild)		4. RHF (Inotropic Support)	
	All						
	N	N	%	N	%	N	%
3 Month	34	32	94.12	1	2.94	1	2.94
6 Month	26	26	100.00
1 Year	10	10	100.00

GROUP=STS Intermacs

Follow-up Visit	RHF Condition								
	1. No RHF			3. RHF (Mild)		4. RHF (Inotropic Support)		5. RHF (RVAD Support)	
	All								
	N	N	%	N	%	N	%	N	%
3 Month	2347	2079	88.58	96	4.09	168	7.16	4	0.17
6 Month	1771	1629	91.98	64	3.61	75	4.23	3	0.17
1 Year	683	615	90.04	32	4.69	36	5.27	.	.

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021

SITE: HOSPX - DEMO SITE REPORT

Exhibit 49: Patients Implanted at your Center but Excluded from the Cumulative - All Patient Report

Excluded Patient ID	Exclusion Reason	Implant Year
452	Retrospective Patient	2006
631	Pediatric Patient (Age<19)	2007
1060	Patient Implant Date Outside of Report Coverage	2006
4756	Pediatric Patient (Age<19)	2011
5048	Pediatric Patient (Age<19)	2011
5561	Retrospective Patient	2010
5590	Retrospective Patient	2010
5591	Retrospective Patient	2010
5593	Retrospective Patient	2010
7012	Pediatric Patient (Age<19)	2012
107122	Retrospective Patient	2015
116990	Retrospective Patient	2018
125366	Implant, Pre-Implant, or Patient form not validated	2020
125722	Implant, Pre-Implant, or Patient form not validated	2020
126037	Implant, Pre-Implant, or Patient form not validated	2020
126223	Implant, Pre-Implant, or Patient form not validated	2020
126245	Implant, Pre-Implant, or Patient form not validated	2020
126375	Implant, Pre-Implant, or Patient form not validated	2020
126411	Implant, Pre-Implant, or Patient form not validated	2020
126738	Implant, Pre-Implant, or Patient form not validated	2021
126823	Implant, Pre-Implant, or Patient form not validated	2021
126928	Implant, Pre-Implant, or Patient form not validated	2021
127069	Implant, Pre-Implant, or Patient form not validated	2021
127251	Implant, Pre-Implant, or Patient form not validated	2021
127334	Implant, Pre-Implant, or Patient form not validated	2021
127727	Implant, Pre-Implant, or Patient form not validated	2021
127743	Implant, Pre-Implant, or Patient form not validated	2021
127744	Implant, Pre-Implant, or Patient form not validated	2021
127829	Implant, Pre-Implant, or Patient form not validated	2021
127830	Implant, Pre-Implant, or Patient form not validated	2021
127984	Implant, Pre-Implant, or Patient form not validated	2021
128045	Implant, Pre-Implant, or Patient form not validated	2021

STS INTERMACS - Quarterly Quality Assurance Report (2021 Q2) - Recent - Primary VAD Patients

COVERAGE: January 1, 2020 - June 30, 2021


SITE: HOSPX - DEMO SITE REPORT

III. Registry Compliance

Exhibit 50. Compliance

Site compliance is determined by the percentage of all follow-up forms that are due during this reporting period that have been completed. **This calculation has been updated to include ALL follow-up forms expected for ALL patients and ALL devices.** Only active sites that have at least 10 follow-up forms due are included in this figure (n = 172 sites). This exhibit is the same in both cumulative and recent report. It is based on all follow-up forms.

STS InterMACS has defined required compliance as 90%. If your hospital is below 90%, please examine your patient follow-up table that is contained in the STS InterMACS Data Quality Quarterly Report. This table will identify the exact patients who have a 'past due' follow-up form.



BiVAD: BiVentricular Assist Device
BMI: Body Mass Index
BP: Blood Pressure
BSA: Body Surface Area
BTC: Bridge to Candidacy
BUN: Blood Urea Nitrogen
CMS: Centers for Medicare and Medicaid
COPD: Chronic Obstructive Pulmonary Disease
CNS: Central Nervous System
CRP: C - Reactive Protein
CVA: Cerebrovascular Accident
DCC: Data Coordinating Center
DT: Destination Therapy
ECMO: Extracorporeal-membrane Oxygenation
EQ-5D: Euro Quality of Life
FDA: Federal Drug Administration
HF: Heart Failure
IABP: Intra-Aortic Balloon Pump
IgG: Immunoglobulin G
INR: International Normalized Ratio
Intermacs: Interagency Registry for Mechanically Assisted Circulatory Support
LVAD: Left Ventricular Assist Device
LVEF: Left Ventricular Ejection Fraction
LVEDD: Left Ventricular End Diastolic Dysfunction
LVSF: Left Ventricular Shortening Fraction
MCSD: Mechanically Circulatory Support Device
NHLBI: National Heart Lung and Blood Institute
NT pro brain natriuretic peptide: N-Terminal pro brain Natriuretic peptide
NYHA: New York Heart Association
OR: Operating Room
Regurg: Regurgitation
RVAD: Right Ventricular Assist Device
RVEF: Right Ventricular Ejection Fraction
SAE: Serious Adverse Event
SGOT-AST: Serum Glutamic Oxaloacetic Transaminase
SGPT-ALT: Serum Glutamic Pyruvic Transaminase
STS: Society of Thoracic Surgeons
TAH: Total Artificial Heart
TIA: Transient Ischemic Attack
VAD: Ventricular Assist Device
VAS: Visual Analog Scale